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The risk of second malignant neoplasms (SMNs) following prostate radiotherapy is a concern 
due to the large population of survivors and decreasing age at diagnosis. It is known that 
parallel-opposed beam proton therapy carries a lower risk than photon IMRT. However, a 
comparison of SMN risk following proton and photon arc therapies has not previously been 
reported. The purpose of this study was to predict the ratio of excess relative risk (RRR) of 
SMN incidence following proton arc therapy to that after volumetric modulated arc therapy 
(VMAT). Additionally, we investigated the impact of margin size and the effect of risk-
minimized proton beam weighting on predicted RRR. Physician-approved treatment plans were 
created for both modalities for three patients. Therapeutic dose was obtained with differential 
dose-volume histograms from the treatment planning system, and stray dose was estimated 
from the literature or calculated with Monte Carlo simulations. Then, various risk models were 
applied to the total dose. Additional treatment plans were also investigated with varying margin 
size and risk-minimized proton beam weighting. The mean RRR ranged from 0.74 to 0.99, 
depending on risk model. The additional treatment plans revealed that the RRR remained 
approximately constant with varying margin size, and that the predicted RRR was reduced by 
12% using a risk-minimized proton arc therapy planning technique. In conclusion, proton arc 
therapy was found to provide an advantage over VMAT in regard to predicted risk of SMN 
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following prostate radiotherapy. This advantage was independent of margin size and was 
amplified with risk-optimized proton beam weighting.      
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Chapter 1 
Introduction 
 This chapter contains an introduction to prostate cancer (section 1.1) as well as external 
beam photon (section 1.2.1) and proton (section 1.2.2) radiotherapy techniques. The risk of 
second malignant neoplasms from radiation therapy (section 1.3) will be briefly reviewed. 
Finally, the statement of the problem (section 1.4) is followed by the hypothesis and specific 
aims (section 1.5).    
1.1. Prostate Cancer 
 Prostate cancer is a disease with a large incidence and a high survival rate, which translates 
into a substantial population of survivors. It is the most common cancer in men, excluding non-
melanoma skin cancer, with approximately 217,730 new prostate cancer cases diagnosed in the 
United States in 2010 (Jemal et al., 2010). Most cases of prostate cancer are curable; the 
relative 5-year survival rate is nearly 100% and the relative 10-year survival rate is 91% 
(American Cancer Society, 2011). Consequently, as of 2007, there were approximately 2.3 
million prostate cancer survivors in the United States (SEER, 2007).  
 Another factor contributing to the large population of prostate cancer survivors is that men 
are being diagnosed with prostate cancer earlier in life and at an earlier stage of disease 
progression. This is in part due to the development of the prostate-specific antigen (PSA) test, a 
non-invasive blood test which is widely used in assessing a patient‟s risk of prostate cancer 
(American Cancer Society, 2011). The mean age of diagnosis has decreased from 72 years in 
1990 (Quinn and Babb, 2002) to approximately 67 years in 2007 (SEER, 2007). 
 There are multiple effective treatment options for men diagnosed with prostate cancer 
including surgery, hormone therapy, external beam radiation therapy, and low and high dose 
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rate brachytherapy. Active surveillance is also an appropriate option for many men who have 
asymptomatic and slow-growing tumors (American Cancer Society, 2011). The treatment 
strategy for each specific case is determined by the physician and the patient and takes into 
account factors like tumor stage, and the patient‟s age and overall health. 
1.2. External Beam Radiation Therapy 
 External beam radiation therapy (EBRT) is a good treatment option for many patients and is 
a component of approximately one third of all prostate cancer patients‟ therapy (Mettlin et al., 
1997; Virnig et al., 2002). EBRT is, in part, so prevalent due to its effectiveness. D‟Amico et 
al. (1998) reported no statistical difference in biochemical outcomes in patients who were 
treated with radical prostatectomy vs. EBRT for localized prostate cancer. Additionally, EBRT 
has the advantage of being non-invasive and safer than radical prostatectomy for patients with 
lower overall health status by eliminating surgery-specific risks, for example, the risk of 
infection (Culver et al., 1991).  
 However, radiation therapy is not free from risk. Patients can experience acute or late 
effects from radiation due to irradiation of normal tissues. For prostate radiotherapy, acute 
effects can include urinary urgency or incontinence, bowel irritation, and rectal bleeding 
(American Cancer Society, 2011), which usually resolve with time. Some patients experience 
late effects of radiation; for example, patients who survive more than approximately five years 
have an increased risk of developing secondary solid tumor due to radiation exposure (Brenner 
et al., 2000).  
 1.2.1. Photon Therapy 
 Photons have been used for radiation therapy since the early 1900s after Roentgen 
discovered the x-ray in 1895. Many technological advances have improved our ability to 
deliver radiation dose accurately and precisely to tumors and minimize dose to normal tissue. 
Medical megavoltage linear accelerators (linacs), invented in the 1960‟s, provided significant 
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skin sparing compared to lower energy x-ray therapy. Then, in the 1980s, computed 
tomography (CT) imaging made it possible to visualize the target volume on a three-
dimensional (3-D) image. Additionally, it became possible to visualize the dose distribution 
and anatomy in 3-D with treatment planning systems (TPSs). The standard of care then became 
3-D conformal radiation therapy (3DCRT), which refers to radiotherapy that, in addition to 
being planned in 3-D, is shaped in the beam‟s eye view around the target volume to reduce 
dose to normal tissue. These advances facilitated prostate dose escalation from approximately 
65 gray (Gy) to doses in the high 70s of Gy (Thompson, 2007). In the 1990s, intensity 
modulated radiation therapy (IMRT) and image guided radiation therapy (IGRT) became 
available, which provided additional improvement in accurately delivering conformal dose 
distributions. In particular for prostate cancer, Zelefsky et al. (2000) showed that IMRT 
improved coverage of the clinical target volume (CTV), decreased bladder and rectal doses, 
and decreased the incidence of rectal bleeding compared to 3DCRT. 
 The current standard of care for photon EBRT for prostate cancer at The University of 
Texas MD Anderson Cancer Center (MDACC) is IMRT. Linac based IMRT creates conformal 
dose distributions with a multi-leaf collimator (MLC), which modulates the fluence of photons 
across the two-dimensional cross-section of each beam. There are two ways that the MLC can 
operate during the delivery of the treatment beam. The first way is dynamically, also known as 
the sliding window technique, which is achieved by delivering the radiation while the leaves 
move across the field. The second approach is for the beam to turn off while the leaves move to 
the next position, only delivering radiation when the leaves are stationary. This second 
technique is known as step-and-shoot, and is the method implemented at MDACC. Chui et al. 
(2001) and Longobardi et al. (2005) compared the two techniques and found comparable 
dosimetric quality and accuracy between the two (given adequate segments for step-and-shoot, 
approximately 10 per beam). Chui et al. also found that sliding window required approximately 
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20% more monitor units (MUs), but that the overall treatment time was roughly two times 
faster than the step-and-shoot method. 
 The first rotational intensity modulated photon radiotherapy technique, tomotherapy, was 
proposed by Mackie and colleagues and published in 1993 (Mackie et al., 1993). In this 
technique, intensity modulation is accomplished by delivering radiation in slices and setting 
collimating leaves to either fully open or fully closed positions. The first clinical 
implementation of this “slice therapy” was the PeacockTM system (Nomos Corporation, 
Sewickley, PA), which used a MIMiC
TM
 MLC mounted on a linac gantry (Carol, 1994; Carol, 
1995; Mackie, 2006). Treatment was delivered serially, and the treatment couch was advanced 
for the delivery of each adjacent slice. Then, TomoTherapy® Incorporated developed a CT 
scanner type gantry with a linac that rotates and delivers radiation helically while the patient is 
advanced continuously through the bore (Mackie et al., 1999; Yang et al., 1997; Mackie, 
2006). With helical delivery, patient positioning errors were not as critical as with serial 
delivery, where a 1 mm positioning error could cause dose errors of approximately 10-20% 
(Carol et al., 1996; Low and Mutic, 1997). The new technique also significantly reduced the 
treatment time, from the order of 30 minutes for serial delivery (Xia et al., 2000) to a mean 
treatment time of 10.7 minutes for helical delivery (Sterzing et al., 2008).  
 A more recently introduced rotational intensity modulated photon radiotherapy technique, 
which can be administered with a conventional linac, is volumetric modulated arc therapy 
(VMAT). Unlike tomotherapy, an entire volume, instead of a slice, can be irradiated in single 
rotation and with a fixed couch position. The specific method was first published by Otto in 
2008 (Otto, 2008), which expanded on a method proposed and developed by Yu (1995). Both 
dose rate and rotation speed are varied during beam delivery, providing additional degrees of 
freedom in treatment planning. The VMAT optimization algorithm described by Otto was 
implemented in the Eclipse (Varian Medical Systems, Palo Alto, CA) TPS, which 
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approximates an arc as multiple static beams, starting with a low resolution and increasing to 
177 beams as it optimizes, while constraining both the dose rate and the MLC motion to take 
into account the mechanical and radiation limitations of the linac and MLC (Otto, 2008). Our 
institution has treated a small number of patients with VMAT since 2009, including patients 
with prostate cancer. To date, it appears that the main advantage of this technique is shorter 
treatment times while preserving plan quality comparable to IMRT (Kjaer-Kristoffersen et al., 
2009; Zhang et al., 2009; Palma et al., 2008; Bedford and Warrington, 2009). Otto reported 
treatment times between about 1.5 to 3 minutes for one arc. Specifically, delivery time for a 
one-arc nasopharynx VMAT treatment plan was 1.8 minutes, and delivery time for a 
comparable 7-field nasopharynx IMRT plan was 7.1 minutes (Otto, 2008). The experience at 
our institution is that two arcs are required for optimal treatment plans, yielding treatment 
delivery times of approximately three minutes. 
 An undesirable aspect of all EBRT photon radiotherapy techniques is that the patient is also 
exposed to some stray radiation. The sources of this stray radiation are photon leakage from the 
treatment head and MLC leaves, photon scatter from the collimator and the patient, and, above 
approximately 6 MeV, secondary neutrons produced by (γ,n) reactions in the treatment head 
and, to a lesser degree, the patient (Howell et al., 2009; NCRP, 2005). In or near the treatment 
field, scatter is the predominant source of stray radiation, whereas far from the treatment field, 
leakage predominates (Kase et al., 1983; Stovall et al., 1995). Radiation exposures from 
leakage and scatter photons and photoneutrons (for 10 MV photon beams and above) have been 
measured and characterized for conventional therapy (Kase et al., 1983; Stovall et al., 2006), 
IMRT (Kry et al., 2005b; Howell et al., 2006; Wang and Xu, 2008), and tomotherapy (Ramsey 
et al., 2006). Also, Xu et al. (2008) have published a review on the topic. To our knowledge, 
there have not been any reports on leakage and scatter exposures for VMAT. However, some 
studies have implicitly made the assumption that the stray radiation dose from VMAT is 
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equivalent (per MU) to that from IMRT (Palma et al., 2008; Kjaer-Kristoffersen et al., 2009; 
Wolff et al., 2009; Yoo et al., 2010). To date, VMAT has only been used with 6 MV, thus 
secondary neutrons are not a concern. 
 1.2.2. Proton Therapy 
 Robert Wilson proposed the medical use of protons in the treatment of tumors in 1946 
(Wilson, 1946). In his paper, Wilson described the advantageous dosimetric properties of 
protons, namely, how they deposit a large portion of their dose in the last few millimeters of 
their range near the peak of the Bragg curve (Figure 1.1). Beyond their range, determined by 
their initial kinetic energy, the dose falls rapidly to almost zero, thus enabling sparing of the 
tissue distal to the target. 
Proton Bragg Peak 122.5 MeV
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Figure 1.1 – Relative absorbed dose of a simulated Bragg curve from an unmodulated 122.5 
MeV proton beam vs. depth in water.   
 
 The first therapeutic use of proton therapy in humans was for the pituitary gland in 1954 
(Lawrence et al., 1958), then for brain tumors shortly after (Kjellberg et al., 1962; Larsson et 
al., 1963; Kjellberg and Kliman, 1973; Munzenrider and Liebsch, 1999). Later, proton therapy 
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was also extensively used in the treatment of ocular tumors, chordomas, and chondrosarcomas 
(Munzenrider et al., 1980; Suit et al., 1982; Gragoudas, 1986; Munzenrider, 1999).  
 To date, over 67,000 patients have been treated with proton therapy, and there are 
approximately 28 centers in operation world-wide (Particle Therapy Co-Operative Group, 
2010). Of this large population of proton therapy patients, prostate cancer patients are the 
majority (Sisterson, 2005), which have resulted in disease-free survival rates comparable to 
other forms of local therapy and minimal morbidity (Slater et al., 2004; Nihei et al., 2010). 
 Proton therapy dose is prescribed differently than photon therapy dose. Proton beams are 
believed by some to have a slightly higher relative biological effectiveness (RBE) compared to 
photon beams (ICRU, 2007). To attempt to account for these differences, the ICRU 
recommends a generic RBE value of 1.1 and that the dose be prescribed in units of Gy (RBE), 
where DRBE[Gy (RBE)] =  Dabsorbed[Gy]  RBE. This convention is controversial, but is widely 
used.  
 There are two main methods to cover the cross-sectional area of a target volume with a 
proton beam (Chu, 1993). The first method to provide lateral coverage of the target is to spread 
the pencil beam into a larger field. The second method is to “sweep” the pencil beam across the 
target using deflecting magnets. These two modes of delivery are referred to as passive 
scattering and beam scanning (or active scanning), respectively, and passive scattering is far 
more prevalent around the world (Sisterson, 2005).   
 Passive scattering is achieved by spreading the pencil beam of protons into a large, uniform 
field with scattering foils. A double scattering approach was proposed by Koehler et al. (1977) 
and uses a first scatterer to spread the beam, a central beam stop to eliminate the protons in the 
center of the field, and then a second scatterer to further spread the beam to produce a large and 
relatively uniform proton field. This approach was subsequently refined by Gottschalk and 
others and is simple, safe, and versatile (Gottschalk et al., 1991). 
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 It is also necessary to broaden the high dose region over the target volume in depth. A 
proton‟s range is determined by its energy, where a higher energy results in a longer range. 
Therefore, modulating the beam‟s energy will modulate the beam range. One method is to use a 
range modulator wheel (RMW), which has steps of varying thickness of absorbing material to 
modulate the range (Chu, 1993). The RMW rotates quickly through the beam to produce 
multiple Bragg peaks with varying range. The summation of these modulated pristine peaks 
produces a spread-out Bragg peak (SOBP) of a desired width (Figure 1.2). This was proposed 
by Wilson (1946) and implemented by Koehler et al. (1975) at the Harvard Cyclotron 
Laboratory.  
 
Figure 1.2 – Relative absorbed dose from a spread-out Bragg peak, B, of 14.5 cm width 
resulting from the sum of the pristine Bragg curves such as A (Koehler et al., 1975).  The 
depths and magnitudes of the shifted Bragg curves relative to A are denoted by the triangles 
labeled1-17. Reprinted from Nuclear Instruments and Methods, 131, A.M. Koehler, R.J. 
Schneider, J.M. Sisterson, Range modulators for protons and heavy ions, 438, 1975, with 
permission from Elsevier 
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 After a proton beam is spread laterally (cross-field direction) and longitudinally (depth 
direction), further modifications are required to conform the beam to the target volume. Beam-
specific brass apertures are used to collimate the cross-section of the beam to the shape of the 
target (Wagner, 1982). In addition, to conform the distal end of the SOBP to the target, a beam-
specific range compensator is milled to pull the range of the protons back where necessary 
(Wingate et al., 1977; Goitein, 1978; Wagner, 1982; Urie et al., 1984).   
 In recent years, interest in rotational delivery of proton beams has increased. To our 
knowledge, the first appearance of proton arc therapy in the literature was in 1997, when three 
separate groups published studies on the topic. The first publication was a simulation study for 
a Ewing sarcoma treatment (Isacsson et al., 1997), the second publication was a phantom study 
for a chest wall irradiation (Sandison et al., 1997), and the third publication was a patent for a 
method and apparatus for proton arc therapy (Deasy, 1997). Since proton arc therapy‟s 
appearance in the literature, various other papers have been published. Oelfke and Bortfeld 
(2000) reported a factor of 2 – 3 reduction in integral dose to healthy tissue for inverse planned 
proton arc therapy when compared to photon IMRT for a simulation of irradiation of a planar 
circular target. Similarly, Flynn et al. (2007) found the integral dose was lowered by a factor of 
about 2 for proton arc therapy compared to photon IMRT and helical tomotherapy. Sengbusch 
et al. (2009) investigated the energy required to treat patients with proton arc therapy and found 
that, with an AP arc and a PA arc, each subtending 90 degrees, 90% of the patients in their 
study could be treated with a proton kinetic energy of 198 MeV or less. One particular design 
for a compact proton accelerator capable of arc delivery is under commercial development by 
TomoTherapy Incorporated (Madison, Wisconsin) in partnership with Lawrence Livermore 
National Laboratory (Mackie et al., 2007; Caporaso et al., 2008; Chen, 2009). This design 
proposes to use the dielectric wall accelerator technology to achieve a “one room” proton 
therapy delivery system capable of simultaneous scanned beam delivery and gantry rotation.  
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 One of the reasons for this interest in proton arc therapy is the potential improvement in 
conformity that arc therapy could provide. Currently, IMRT rivals proton therapy with regard 
to dose conformity due to the comparatively large number of treatment gantry angles used in 
IMRT (Bortfeld, 2006; Trofimov et al., 2007). However, it is possible that by increasing the 
number of beam angles (or a delivering through an arc) proton therapy could provide 
significantly better conformity than IMRT or VMAT. 
 Theoretically, one can deliver proton arc therapy with current proton gantries using the 
passive scattering technique. For example, the SOBP width can be varied throughout the 
rotation by altering the gating of the beam through different steps of the range modulator 
wheel. Then, the range could be varied by using a robotic wedge energy degrader (Chu, 1993; 
Lu, 2008a, b; Titt et al., 2010; Melancon, 2010), and the shape of the beam could be defined by 
a proton-appropriate MLC (Brahme et al., 1987; Chu, 1993; Bues et al., 2005; Slopsema and 
Kooy, 2006; McDonough and Tinnel, 2007). While many technical aspects of proton arc 
delivery still require research and development, there are no known fundamental obstacles to its 
implementation. 
 One poorly understood aspect of proton arc therapy is the exposure of patients to stray 
radiation. Similar to photon therapy, proton therapy patients are also exposed to stray radiation, 
which originates from neutrons produced in (p, xn) reactions. These neutrons can be produced 
externally by reactions in the treatment unit, or internally by reactions in the patient‟s body. 
Since the spot scanning technique uses magnetic fields to laterally spread the beam instead of 
scattering foils, external neutron production is comparatively small (Schneider et al., 2002). 
However, with optimized design, neutron production in passively scattered proton treatment 
units can be reduced (Tayama et al., 2006a; Taddei et al., 2008; Brenner and Hall, 2008; 
Taddei et al., 2009a), diminishing the advantage of scanning delivery. The neutrons produced 
in the passive scattering technique are dependent on the general construction of the beam 
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nozzle and increases with increasing proton beam energy, increasing SOBP width, increasing 
uncollimated proton field size, and decreasing aperture size (Yan et al., 2002; Mesoloras et al., 
2006; Zheng et al., 2008a; Taddei et al., 2008). Neutron dose values from the literature vary 
dramatically between different facilities, suggesting a strong dependence on delivery technique, 
facility design, and the method of measurement or simulation (a sample of which are plotted in 
Figure 1.3) (Schneider et al., 2002; Yan et al., 2002; Fontenot et al., 2005b; Polf et al., 2005; 
Hall, 2006; Mesoloras et al., 2006; Tayama et al., 2006a; Zheng et al., 2007a; Moyers et al., 
2008b; Wang et al., 2010; Yonai et al., 2010; Zhang et al., 2010; Clasie et al., 2010). These 
values range from 0.025 millisieverts per gray (mSv/Gy) (Mesoloras et al., 2006) to 8.92 
mSv/Gy (Schneider et al., 2002; Hall, 2006).  
 
Figure 1.3 – Stray neutron equivalent dose per therapeutic absorbed dose (H/D) for proton 
beams as a function of distance from proton field edge (Schneider et al., 2002; Yan et al., 2002; 
Fontenot et al., 2005b; Polf et al., 2005; Hall, 2006; Mesoloras et al., 2006; Tayama et al., 
2006a; Zheng et al., 2007a). For comparison, values are also plotted for 6 MV IMRT (navy) 
and 6 MV 4 field CRT (pink) (Hall, 2006).   
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 There have been some stray equivalent dose measurements and simulations specifically for 
proton therapy of the prostate (Wroe et al., 2007; Fontenot et al., 2008; Zheng et al., 2008a; 
Taddei et al., 2008; Wroe et al., 2009; Newhauser et al., 2009b; Yepes et al., 2009). For 
example, Wroe et al. performed measurements at Loma Linda University Medical Center 
(2007) and Massachusetts General Hospital (2009), which ranged from 0.1 mSv/Gy to 10 
mSv/Gy, depending on facility and distance from isocenter. One study from our institution was 
reported by Zheng et al. (2008a), in which the effective dose was found to be 8 mSv/Gy for 
proton therapy of the prostate. Additionally, Fontenot et al. (2008) simulated stray neutron 
doses resulting from a prostate therapy treatment at our institution and found doses ranging 
from 1.9 mSv/Gy to 12.3 mSv/Gy, where dose decreased with increasing distance from 
isocenter. In a similar study, Taddei et al. (2008) found equivalent doses ranging from 1.05 
mSv/Gy to 19.7 mSv/Gy. 
1.3. Risk of Second Malignant Neoplasms from Radiation Therapy 
 Ionizing radiation damages cells, and when damaged cells are not sterilized, they have the 
potential to mutate and become carcinogenic (Preston et al., 2007). Therefore, patients 
receiving radiation therapy are at increased risk for the development of a second primary 
cancer, or second malignant neoplasm (SMN) (NRC, 2006). 
 Epidemiological studies on the risk of SMN incidence following prostate radiotherapy are 
not coherent. Some studies report an increased risk of an SMN, including cancers of the 
bladder and rectum (Brenner et al., 2000; Moon et al., 2006; Kendal et al., 2007). However, 
one study reported an increased risk of bladder cancer but not rectal cancer (Curtis et al., 2006). 
Interestingly, Chrouser et al. (2005) only found an increased risk of bladder cancer in those 
patients who had a prostatectomy prior to radiotherapy, and Pickles and Phillips (2002) found 
an increased risk of bladder cancer in non-irradiated patients but not in irradiated patients. 
While much uncertainty remains regarding risk of SMN following prostate radiotherapy, the 
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absolute risk of incidence of a radiogenic second malignant neoplasm is most likely on the 
order of a percent or two: 0.3% for all patients, and 1.4% for patients who survive at least 10 
years (Brenner et al., 2000). 
 While epidemiological data would be ideal for assessing risks, large follow-up times are 
required and the quality and completeness of dosimetric information is often lacking; therefore, 
it is not feasible to use any single epidemiological study predict patient-specific risk following 
current radiotherapy techniques. In order to predict patient-specific risk of SMN incidence 
following a particular radiotherapy treatment or to compare the predicted risk between different 
treatments, a rigorous, reproducible, and well-understood method is required. First, an accurate 
and complete knowledge of the dose distribution in the organs of interest is needed. Then, the 
relationship between radiation dose and the risk of SMN incidence can be applied to the 
dosimetric information. These methods were previously developed and applied to studies of 
proton therapy and IMRT for prostate cancer (Kry et al., 2005a; Schneider et al., 2007; Taddei 
et al., 2008; Fontenot et al., 2009; Bednarz et al., 2010), but not for arc therapies. The current 
state of knowledge in radiation risk estimation is briefly reviewed below.    
 It is generally accepted that there is a linear-no-threshold (LNT) relationship between 
equivalent doses and risk of cancer between 0 Sv and about 2.5 Sv (NCRP, 1993; NRC, 2006); 
however, the relationship between dose and risk at higher doses is less well understood. At 
higher doses, cell sterilization increases, and the general relationship between dose and risk for 
most tissues most likely lies somewhere between a linear and a linear-exponential model (Hall 
and Wuu, 2003; Sachs and Brenner, 2005; Schneider et al., 2007; Schneider et al., 2006; 
Schneider et al., 2005). 
 Not surprisingly, different tissues have been shown to exhibit different risk relationships 
with dose (Boice et al., 1988; Lindsay et al., 2001; Hall and Wuu, 2003; Dasu and Toma-Dasu, 
2005; Schneider et al., 2005; Sachs and Brenner, 2005) (Figure 1.4).  For example, risk of an 
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SMN in the thyroid has been shown to exhibit a linear-exponential relationship with dose, 
increasing linearly to an inflection point at approximately 20 - 30 Gy, then decreasing at higher 
doses (Thompson et al., 1994; Ron et al., 1995; Sigurdson et al., 2005; Ronckers et al., 2006; 
Bhatti et al., 2010). In stark contrast, the risk of an SMN in the breast has been shown to 
increase linearly to approximately 40 Gy while showing no evidence of decrease at high doses 
(Travis et al., 2003; Travis et al., 2005; Inskip et al., 2009).  
 The dose-risk relationships of the bladder and rectum are of particular interest to this work. 
For the bladder, some evidence indicates that the risk of an SMN may plateau beyond 
approximately 10 Gy (Boice et al., 1988; Neugut et al., 1997; Brenner et al., 2000; Ruben et 
al., 2008). There is less data regarding the rectum, but in a study by Schneider et al. (2005), the 
risk for all organs was assumed to have a linear-exponential relationship to dose, and the organ-
specific exponential term was solved for based on epidemiological data from patients who 
received radiotherapy for Hodgkin‟s disease. Their model for the colon (which includes the 
rectum) has an inflection point at approximately 2 Gy. 
 
   
 15 
Figure 1.4 - Summary of the data showing the relationship between risk of second cancer and 
dose from the A-bomb survivors and cancer survivors treated with radiotherapy (Ruben et al., 
2008). Reprinted from the International Journal of Radiation Oncology Biology Physics, 70, 
Jeremy D. Ruben, Sidney Davis, Cherie Evans, Phillip Jones, Frank Gagliardi, Matthew 
Haynes, Alistair Hunter, Risk of Second Malignant Neoplasms following VMAT and Proton 
Arc Therapy for Prostate Cancer, 1532, 2008, with permission from Elsevier. 
 
  Using the risk models from the literature, Fontenot et al. (2009) predicted the risk of 
SMN incidence (including fatal and non-fatal cancers) following both IMRT and proton 
therapy for three prostate cancer patients (of small, medium, and large anatomical stature). 
Specifically, the authors used detailed dosimetric information, including stray dose, and applied 
risk models to calculate the risk to each organ. In order to cover the range of possible dose-
response relationships indicated by the data in the literature, they applied the LNT model 
(NRC, 2006), the linear-exponential model, and the linear-plateau model. Furthermore, they 
investigated high-dose (40 Sv) and low-dose (10 Sv) inflection points for the linear-exponential 
and linear-plateau models, spanning the values reported in the literature. The specific quantities 
they chose to describe risk were the excess relative risk (ERR), where  
                                  1
Population edin Unexpos Rate
Population Exposedin  Rate
ERR ,                                      (1.1) 
and the ratio of excess relative risk (RRR), where  
                                               
IMRT
apyProtonTher
ERR
ERR
RRR .                                                        (1.2) 
They found, for all risk models considered, that the ERR of an SMN was less for proton therapy 
than for IMRT (Fontenot et al., 2009) (Figure 1.5) within the uncertainties of the calculation 
(Fontenot et al., 2010). It was also found that the in-field radiation in the bladder and rectum 
had the largest impact on the ERR. Furthermore, passively scattered (RRR = 0.66) and scanned 
(RRR = 0.56) proton therapies both conferred significantly lower predicted risk of SMN 
incidence than IMRT.  
   
 16 
 
Figure 1.5 – The predicted risk of SMN incidence following IMRT and proton therapy of the 
prostate from various risk models (Fontenot et al., 2009). It can be seen that the ERR of an 
SMN following IMRT is consistently higher than following proton therapy, and by 
approximately the same ratio (RRR). Reprinted from the International Journal of Radiation 
Oncology Biology Physics, 74, Jonas D. Fontenot, Andrew K. Lee, Wayne D. Newhauser, Risk 
of Secondary Malignant Neoplasms from Proton Therapy and Intensity-Modulated X-Ray 
Therapy for Early-Stage Prostate Cancer, 621, 2009, with permission from Elsevier.  
 
1.4. Statement of the Problem 
 The risk of SMN incidence following radiotherapy of the prostate is a potentially large 
public health concern due to the large population of survivors. SMN risk has been estimated for 
a few case studies following IMRT and proton therapy (Kry et al., 2005a; Schneider et al., 
2006; Schneider et al., 2007; Taddei et al., 2008; Fontenot et al., 2009; Bednarz et al., 2010); 
however, VMAT and proton arc therapy are nascent and proposed modalities, respectively, 
whose impact on risk of second cancer has not been previously reported. Both are new arc 
modalities which distribute the therapeutic dose in a different way than their static counterparts. 
In particular, while arc delivery achieves very conformal distributions in the target region, it 
spreads lower dose over notably more tissue than static delivery (Kjaer-Kristoffersen et al., 
2009; Zhang et al., 2009). Thus, the effect of the differences between static beam and arc 
delivery on predicted risk is not obvious and requires quantitative investigation. 
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 It is also unknown how the margin size around the clinical target volume (CTV) to create 
the planning target volume (PTV) affects predicted risk of an SMN for VMAT and proton arc 
therapy. The required margin size depends on the internal motion, imaging, immobilization, 
setup uncertainty, and the institution‟s experience (ICRU, 1999, 2007). With better 
immobilization and image guided radiotherapy, margin sizes could be reduced. It is expected 
that the predicted risk of an SMN will decrease with smaller margin sizes. 
1.5. Hypothesis and Specific Aims 
 The hypothesis of this study is that the predicted RRR of SMN incidence in the bladder 
and rectum 10 years following proton arc therapy relative to that following VMAT will be 
less than one for prostate cancer for a typical patient exposed at age 60. 
 This hypothesis was tested through the following three specific aims: 
Specific Aim 1: To predict the RRR of SMN incidence following proton arc therapy compared 
to that following VMAT using calculated dose distributions combined with risk models from 
the literature. 
Specific Aim 2: To investigate the impact of uniform vs. variable beam weighting for proton 
arc therapy based on various host and treatment factors, such as type of second cancer and 
avoidance of a hip prosthesis, on the predicted RRR. 
Specific Aim 3: To examine the sensitivity of the predicted ERR and RRR on the margin size 
around the clinical target volume following proton arc therapy compared to that following 
VMAT. 
General Methodology 
 Three patients were selected for this study. For specific aim 1, treatment plans for both 
VMAT and proton arc therapy were created for each patient, yielding 6 “nominal” treatment 
plans. Then, the risk of SMN incidence was predicted for each treatment plan using three 
different risk models: the linear-no-threshold, linear-exponential, and linear-plateau models. 
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For specific aim 2, variable beam weighting was applied to one of the proton arc plans that was 
created for specific aim 1, and its impact on risk of SMN incidence examined. Finally, for 
specific aim 3, the margins around the CTV were varied, and new treatment plans were created 
for each margin expansion for both VMAT and proton arc therapy. For each new margin plan, 
the risk of an SMN was predicted to investigate the relationship between risk and margin size.
  
 
Chapter 2 
Methods and Materials 
 This chapter describes the methods and materials used in this work, beginning with the 
patient selection and volume contouring (2.1). Then, the methods for treatment planning and 
therapeutic dose determination (2.2) is covered, with details pertaining to VMAT (2.2.1) and 
proton arc therapy (2.2.2). Next, the estimation of stray dose (2.3) is discussed with specifics 
regarding VMAT (2.3.1) and proton arc therapy (2.3.2). Subsequently, the method used to 
predict risk of an SMN is discussed (2.4) with specifics regarding the LNT model (2.4.1) and 
the alternate risk models (2.4.2), followed by an example calculation for each (2.4.3). Finally, 
the methods section concludes with a review of the methods used for statistical analysis (2.4.4) 
and uncertainty analysis (2.4.5), and a summary of the risk calculations performed (2.4.6). 
2.1. Patient Selection and Contouring 
 We selected three patients who were previously studied by Fontenot et al. (2009) in a 
comparison of the risk of SMN incidence following IMRT and parallel-opposed beam proton 
therapy for prostate cancer. For their study, patient information was obtained, in accordance 
with an institutional review board protocol, from electronic records of patients who were 
treated at our institution for prostate cancer. A group of 72 patients who were treated in 2007 
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were analyzed in order to identify patients who represented small, medium, and large patients 
of the sample based on the range (90% distal dose fall-off) of the lateral proton beam to cover 
the target volume (prostate, proximal seminal vesicles, and margin). The mean range of the 
lateral beams was 24.7 cm, with a standard deviation of 1.2 cm. The mean range was 
determined to be representative of a “medium” patient, and similarly the mean range plus and 
minus 2σ of the mean range to be representative of a “large” and “small” patient, respectively. 
A summary of the patients who most closely matched the mean, mean plus 2σ, and mean minus 
2σ ranges is presented in Table 2.1.  
Table 2.1 - Patient age at exposure, stage of cancer, and range of the proton beam for the 
selected small, medium and large patients (Fontenot, 2008). 
Patient 
Size 
Patient Age 
at time of 
Treatment 
Adeno-
carcinoma 
stage 
Beam 
Range 
Formula 
Calculated 
Range (cm) 
Small 60 yr T2a Mean - 2σ 22.3 
Medium 56 yr T2a Mean 24.7 
Large 46 yr T1c 
Mean + 
2σ 
27.0 
  
 The same organ and structure contours were used for the photon and proton treatment plans 
for each patient in order to consistently compare the plans. These physician-approved contours 
included the CTV, PTV, prostate, bladder, rectum, seminal vesicles, and femoral heads. In 
addition, bladder wall, rectal wall, and various size additional PTV contours were created. The 
bladder wall and rectal wall thicknesses were defined as 5 mm and 3 mm, respectively (Manieri 
et al., 1998; Huh et al., 2003), using the automatic margin and Boolean operator tools in the 
TPS. Slight manual edits were made when the organ wall was clearly visible and the 
automatically created contour did not match the visible anatomy. The three patients in this 
study were previously treated with proton therapy, and VMAT and proton arc therapy treatment 
plans were retrospectively created for the purpose of this study. At the time of simulation, 
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rectal balloons were used to immobilize the prostate and these immobilization devices were 
visible on the CT images.  
2.2. Treatment Planning and Therapeutic Dose Determination 
 All treatment plans were created using a commercial treatment planning system 
(Eclipse, Varian Medical Systems, Palo Alto, CA). The MDACC clinical dose-volume 
histogram (DVH) constraints (In-house dosimetry guideline, 2009) were used for planning and 
evaluation of all plans (Table 2.2). Two treatment plans were created for each patient for 
specific aim 1, one for each modality, and each of the resulting six nominal treatment plans 
were reviewed, revised as needed, and approved by a board certified radiation oncologist. 
Additional treatment plans were created for specific aims 2 and 3.  
Table 2.2 - Dose volume histogram constraints used for VMAT and proton arc therapy 
planning. „D‟ followed by a subscript number corresponds to the percent volume of the organ 
receiving at least the listed dose constraint, where dose for VMAT is in units of Gy and dose 
for proton arc therapy is in units of Gy (RBE). For example, D20 ≤ 70 means that 20% of the 
volume should receive no more than 70 Gy or Gy (RBE). 
Organ DVH Constraints 
Bladder D20 ≤ 70 Gy or Gy (RBE) 
Rectum 
D60 ≤ 40 Gy or Gy (RBE) 
D50 ≤ 45 Gy or Gy (RBE) 
D40 ≤ 60 Gy or Gy (RBE) 
D20 ≤ 70 Gy or Gy (RBE) 
D15 ≤ 76 Gy or Gy (RBE) 
D5 ≤ 80 Gy or Gy (RBE) 
Femoral Heads D15 ≤ 45 Gy or Gy (RBE) 
 
 For specific aim 1, the PTV was defined for all patients using margins specified by the 
current MDACC standard-of-care, which is referred to as the nominal PTV. The CTV was 
   
 21 
expanded by 5 mm posteriorly and 7 mm in all other anatomical directions. Then, additional 
PTVs with smaller and larger margins were created for the medium patient for specific aim 3. 
All PTVs were created using the “margin for structure” tool to expand the CTV (Figure 2.1).  
 
Figure 2.1 - Axial (left) and sagittal (right) CT slices showing the prostate (blue), PTV (red), 
the rectum and contents (green), and the bladder and contents (yellow) for the nominal PTV 
(top), a smaller PTV (middle), and a larger PTV (bottom). Notice the decreased amount of 
normal tissue encompassed within the smaller PTV and the increased amount of normal tissue 
encompassed within the larger PTV. 
 
 In this study the majority of the additional PTVs were smaller than the nominal PTV 
because it is likely that future improvements in immobilization and imaging technologies will 
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enable smaller margins, i.e. a reduction from our current nominal PTV margins. We used 
margin expansions ranging from 0 mm (the theoretical limit) to 6 mm posteriorly and 8 mm in 
all other anatomical directions. A detailed list of all PTV margins used in this study can be 
found in Table 2.3.  
Table 2.3 – Variable CTV expansion margins used to create different PTVs and their 
differences from the nominal expansions. “Else” refers to all anatomical directions other than 
posterior. 
Plan 
Index 
Posterior 
Expansion 
(mm) 
Else 
Expansion 
(mm) 
Posterior 
Difference 
from 
Nominal 
(mm) 
Else 
Difference 
from 
Nominal 
(mm) 
 
 
Comment 
- 5 7 0 0 Nominal 
1 0 0 -5 -7 Smallest 
2 0 2 -5 -5  
3 2 4 -3 -3  
4 3 5 -2 -2  
5 4 6 -1 -1  
6 6 8 1 1 Largest 
 
 2.2.1. Volumetric Modulated Arc Therapy 
 The Eclipse TPS (Version 8.6) was used for VMAT planning. Dose was computed with the 
Anisotropic Analytical Algorithm (AAA) (Van Esch et al., 2006) with heterogeneity 
corrections and a 2.5 mm calculation grid. The TPS was commissioned for clinical use at our 
institution (R. M. Howell, pers. comm.). All of the VMAT plans were planned with 6 MV 
photons to a prescribed mean dose of 76 Gy to the PTV in 38 fractions. Then, in accordance 
with the standard-of-care, a normalization was applied to provide coverage of the 76 Gy 
isodose line around the PTV, 96.4% was the largest normalization required, and, in order for 
the prescription dose to be a control in this study, the normalization of 96.4% was applied to all 
plans. The photon absorbed dose in gray is equal to the equivalent dose in sieverts due to a 
radiation weighting factor of 1 for photons (ICRP 1990).  
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 VMAT treatment planning for this study was consistent with the MDACC clinical practice 
(R. M. Howell, pers. comm.). Each treatment plan had two overlapping 220 degree arcs, each 
subtending the angle from 110 to 250 degrees (one clockwise and one counter clockwise arc). 
Two arcs double the possible number of control points and allows a higher degree of 
modulation, and the 60 degree gap minimizes entrance dose to the rectum (Figure 2.2). The 
collimator rotation was set to 30 degrees for the first arc and 330 degrees for the second to 
minimize overlap of inter-leaf leakage from the two arcs. In addition, for beam optimization 
purposes, avoidance structures were used to further conform the dose. For example, constraints 
were applied to a rectal avoidance volume that included the posterior portion of the rectum. 
 
Figure 2.2 – Illustration of the two arcs used for VMAT treatment planning. It can be seen that 
the angle and modulation (orange lines inside yellow field lines, which are visible on the 
counterclockwise arc) spare the rectum (green) of entrance dose. 
 
 For specific aim 1, treatment plans were optimized for the nominal PTV for the small, 
medium, and large patients. For specific aim 3, additional treatment plans were optimized for 
each of the alternate PTVs for the medium patient. The same objectives and constraints were 
used for both the nominal and alternate PTVs (Table 2.3). Therefore, the main difference 
between these treatment plans was the volume of the high-dose region. 
counterclockwise arc clockwise arc 
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 2.2.2. Proton Arc Therapy 
 The Eclipse TPS (Version 8.9) was used for proton arc therapy planning. Dose was 
computed with a proton pencil beam algorithm (Schaffner, 2008) with heterogeneity 
corrections and a 2.5 mm calculation grid. The TPS was previously configured and tested for 
proton radiotherapy at our institution (Newhauser et al., 2007b). The prescribed mean dose was 
76 Gy (RBE) to the PTV in 38 fractions. Then, similarly to the VMAT plans (section 2.2.1), all 
plans were normalized to 96.4%, resulting in a mean dose of 78.8 Gy (RBE) to the PTV. 
Treatment planning techniques for photon arc therapies are approximated with static treatment 
beams (Mackie et al., 1993; Yu, 1995; Otto, 2008; Bzdusek et al., 2009). In the same way, we 
approximated proton arc delivery in the TPS with static, discrete treatment beams, each 
representing an arc segment centered at the beam angle (Flynn et al., 2007). 
 In order to determine the number of static proton beams required for a reasonable 
approximation in the treatment planning of arc delivery, treatment plans with 4, 6, 8, 12, 16, 24, 
and 32 equally spaced gantry angles were investigated. Because the dose distribution in a 4-
beam plan with angles of 0, 90, 180 and 270 degrees depended on starting angle for a coarse 
beam resolution, a second 4-beam treatment plan was created with beam angles of 45, 135, 
225, and 315 degrees. The mean doses to the bladder (and contents), bladder wall, rectum (and 
contents), rectal wall, femoral heads, and normal tissue of the pelvis were plotted vs. the 
number of beams to test for dosimetric sensitivity to the choice of beam number in 
approximating arc plans.  
 Based on the results of the above experiment (results are described more fully in section 
3.1.2), we found that sixteen beams were adequate to approximate arc therapy for the purposes 
this study. The sixteen beams were equally spaced at the angles of 22.5, 45, 67.5, 90, 112.5, 
135, 157.5, 180, 202.5, 225, 247.5, 270, 292.5, 315, 337.5, and 360 degrees around the patient, 
where each static beam approximated 22.5 degrees of arc delivery.  
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 Unlike the procedure used for VMAT treatment planning, the PTV was not explicitly used 
to design the proton treatment plans. Instead, margins around the CTV were selected to provide 
conservative coverage, which consequently encompassed the PTV within a high dose region. A 
generic PTV is not suitable as the primary planning volume for proton therapy because it is a 
geometrical concept that assumes the “static dose cloud approximation” (Unkelbach et al., 
2009). Under this approximation, it is assumed that the location in space and shape of the dose 
distribution are virtually unaffected by changes in the anatomy, e.g. setup errors or tumor 
motion. This approximation is appropriate for photon therapy, but not for proton therapy where 
changes in anatomy or positioning could cause range errors (Urie et al., 1984; Zhang et al., 
2007; Lomax, 2008; Unkelbach et al., 2009). The ideal margins around the CTV are 
determined based on factors like beam range, SOBP width, and uncertainties in delivery such 
as motion (Moyers et al., 2001; Moyers and Miller, 2003; ICRU, 2007). A diagram of how 
proton therapy treatment margins are usually defined is shown in Figure 2.3.  
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Figure 2.3 - Margins defined in treatment planning for proton therapy of the prostate. Proximal 
and distal margins are defined as the distance from the CTV to the edge of the SOBP. Lateral 
margins are defined as the distance from the CTV to the lateral field edge The labels anterior 
and posterior could apply to lateral, proximal, or distal margins, depending on beam direction. 
For example, an anterior-posterior beam would have a posterior distal margin at the end of 
range of the beam. The box defined by the SOBP and the field edges is the high-dose region, 
which should at least encompass the PTV.  
 
 For all gantry angles, the margins, border smoothing, and compensator smearing (Urie et 
al., 1984; Urie et al., 1986) were determined based on techniques that were the standard-of-care 
for lateral opposed proton therapy for prostate cancer at MDACC in 2010 (In-house dosimetry 
guideline, 2009). The lateral margin from the CTV was set to 1.7 cm, and reduced by 0.2 cm 
posteriorly to 1.5 cm to provide rectal sparing for the 6 lateral-most beams (67.5, 90, 112.5, 
247.5, 270, and 292.5 degrees). Then, a “test beam” was applied to each field to cover the CTV 
with zero margins, and the SOBP and range of each “test beam” were used to calculate the 
treatment parameters. The distal margins were calculated as 3 mm plus 3.5% of the range, and 
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the proximal margins were calculated as 3 mm plus 3.5% of the range minus the SOBP width 
(Moyers et al., 2001). The border smoothing was set to the typically used standard-of-care 
value of 1 cm. The compensator smearing was found by taking the quadratic sum of 3% of the 
range and the sum of setup and motion uncertainty. Anterior-posterior (AP) and posterior-
anterior (PA) beams are not part of the standard-of-care at our institution. However, it was 
desired to replicate the rectal sparing provided by the 0.2 cm posterior reduction in the lateral 
margins in the AP and PA beams. In order to provide this sparing, 0.2 cm was subtracted from 
the posterior margins of the 6 AP- and PA–most beams (22.5, 157.5, 180, 202.5, 337.5, and 
360 degrees). Then, the margins, border smoothing, and compensator smearing were applied in 
the TPS to calculate the final treatment beams (which resulted in a final range and SOBP for 
each beam). Following this method, treatment plans with uniform beam weighting were created 
for the small, medium, and large patient for specific aim 1, and were defined as the nominal 
proton arc treatment plans for these patients. 
 Specific aim 2 investigated the dosimetric impact of variable beam weighting for the proton 
arc therapy plan for the medium patient. The ERR of SMN incidence attributed to the 
therapeutic dose from each individual beam was determined using an LNT risk model (section 
2.4) and minimized using a gradient search algorithm (Microsoft Office Excel 2003, Microsoft 
Corporation, Redmond, WA). Corresponding contralateral beams (Figure 2.4) had nearly 
identical risk of an SMN due to anatomical symmetry of the pelvis (for example, 45 and 315 
degrees). Because of this symmetry, the risks from contralateral beams were averaged then 
minimized as a pair of right and left beams with equal weights. The objective function to be 
minimized was based on the risk of an SMN of the bladder, rectum, or a combination of the 
two. However, because the AP and PA beams were on the sagittal axis, these two beams did 
not require a contralateral pair. 
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Figure 2.4 – Illustration of beam pairs. Paired beams are denoted by the same color line. 
Beams were paired because they contributed approximately the same risk of SMN due to the 
symmetry of the pelvis. Because the AP (0/360 degrees) and PA (180 degrees) beams were on 
the sagittal axis, they were not paired.  
 
 Constraints on the optimization ensured that the maximum and minimum weights of each 
beam were within the mechanical and radiation limitations of the treatment unit (Table 2.4). 
The dynamic range of the proton gantry rotation speed was measured to be a factor of 10, 
ranging from 0.1 rpm to 1 rpm. The dynamic range of the dose rate spanned 0.2 Gy/min to 2 
Gy/min. A proton therapy MLC would be required to routinely deliver the proton arc therapy 
plans described in this work, and the maximum MLC leaf speed was estimated from the 
literature to be 3 cm/s (Wijesooriya et al., 2005). The maximum leaf speed required for the 
nominal proton arc treatment plan was determined by measuring the distance from the cranial-
caudal axis at isocenter in 0.5 cm intervals for each aperture, finding the maximum difference 
in distance between consecutive static apertures, then dividing the distance by the minimum 
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time per beam. It was found that the maximum leaf speed required was 0.75 cm/s (ignoring 
acceleration requirements, which were deemed of secondary importance compared to the other 
approximations). Therefore, it was not necessary to explicitly constrain beam weighting based 
on MLC leaf operating characteristics. The treatment time was constrained at 5 minutes or less 
for patient comfort, and facility throughput and efficiency. The constraints in this work were 
estimated for the purpose of theoretically testing the feasibility of proton arc delivery. In 
general, these limitations are facility- and machine-specific. 
Table 2.4 - Constraints placed upon the optimization algorithm to determine beam weighting. 
 
 Sets of optimal beam weights were separately determined for the following objectives: 
minimize the total of risk of an SMN in the bladder and the rectum, the bladder only, and the 
rectum only. The latter two cases are mainly for illustrative purposes, but could have 
hypothetical clinical implications. For example, in the unusual case that a patient has had a 
cystectomy or proctectomy, it would be impossible to induce an SMN in an organ that has been 
removed.  
 An additional special case was considered for specific aim 3. A treatment plan with a set of 
non-uniform beam weights optimized to minimize the risk of second cancers in the bladder and 
rectum was generated for a patient with a prosthetic hip. For this patient, the beams traversing 
through the prosthesis on the ipsilateral side of the patient (67.5, 90, and 112.5 degrees) were 
disallowed due to complications with treating through a large, metal implant including range 
limitations and CT artifacts (Newhauser et al., 2008), then the optimization was performed as 
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before. Due to the asymmetry of the anatomy and limitations on allowed beam angles, beams 
were not mirrored during optimization. 
 A summary of the four optimization objectives for which optimized treatment plans were 
created for specific aim 2 is provided in Table 2.5. 
Table 2.5 – Objectives and constraints for specific aim 2 for which optimal beam weighting 
was found using gradient search optimization. Then, the beam weights were applied to the 
medium patient‟s nominal treatment plan to create risk-minimized plans for each objective.   
 Constraints and Objectives Taken into Account 
Objective Index 
Minimize Risk of 
SMN of Bladder 
Minimize Risk of 
SMN of Rectum 
Forbidden Angles 
[degrees] 
1 Constrained Constrained - 
2 Constrained - - 
3 - Constrained - 
4 Constrained Constrained 67.5, 90, 112.5 
 
 Specific aim 3 investigated the impact of margin size on predicted risk. Therefore, proton 
arc treatment plans were created for the medium patient with varying margins around the CTV, 
each with a corresponding VMAT treatment plan as described in section 2.2.1. However, as 
mentioned previously, there are subtleties regarding the comparison of margins from photon 
and proton plans due to differences in planning procedure (Moyers et al., 2001; Moyers and 
Miller, 2003; ICRU, 2007). Photon plans were directly planned to the PTV, while proton plans 
were planned to the CTV with margins that did not exactly correspond to expansions to a PTV 
(Figure 2.3).  
 As mentioned above, the proton arc plans were not explicitly planned to the PTV. 
Therefore, in order to create plans for specific aim 3, the differences in PTV size from nominal 
(last two columns in Table 2.3) were applied to the nominal proximal, distal, and lateral 
margins around the CTV to produce plans that were appropriate for the different sized PTVs. 
Figure 2.5 illustrates this method, which corresponds to the middle section of the diagram in 
Figure 2.3. The resulting treatment margins and compensator smearing for the treatment plans 
created for specific aim 3 are listed in Tables 2.6 and 2.7.  
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Figure 2.5 - Diagram showing the transformation applied to margins to cover a different sized 
PTV. Here, the PTV below is 3 mm smaller. Therefore, 3 mm is subtracted from all margins to 
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provide the appropriate field size and SOBP to at least encompass the smaller PTV (diagram 
not to scale).  
 
Table 2.6 - Compensator smearing and proximal and distal margins (in cm) from the CTV for 
the proton arc plans. Plan indices correspond to those of the expansions listed in Table 2.3. The 
beams angles are in units of degrees. 
 
 
Table 2.7 - Lateral margins (in cm) from the CTV for the proton arc plans. Plan indices 
correspond to those of the expansion margins listed in Table 2.3. “Rectal Side” refers to the 
posterior margin, which encroaches on the rectum. The beam angles are in units of degrees.  
 
 
2.3. Stray Dose Estimation 
 2.3.1. Volumetric Modulated Arc Therapy 
 Commercial TPSs accurately calculate therapeutic dose (Aspradakis et al., 2003), but 
underestimate stray radiation (Howell et al., 2010a; Howell et al., 2010b). Howell et al. (2010a; 
2010b)  reported that the TPS used in this study underestimated the stray dose by an average of 
40% ± 20% for regions where the reported dose was less that 5% of the prescribed dose. In that 
study, they found that the worst underestimation occurred farthest from the field edge (i.e. very 
low isodose regions).  
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 Therefore, in this study, to more accurately approximate stray radiation, we increased the 
doses that were less than 5% of the prescription dose. This was accomplished by multiplying 
the doses in the differential dose-volume histogram (DVH) ranging from 0% to 5% of the 
prescription dose by 1.4. This procedure was conservative in that the average distance from the 
field edge in our study exceeded that reported by Howell et al. Then, the risk was calculated 
using the modified DVH. 
  2.3.2. Proton Arc Therapy 
Because the commercial TPSs for proton therapy do not predict stray neutron dose, an 
in-house Monte Carlo method was used to predict these values. Monte Carlo methods have 
been used in the past to estimate stray doses for proton therapy (Agosteo et al., 1998; Schneider 
et al., 2002; Paganetti et al., 2004; Fontenot et al., 2005a; Polf and Newhauser, 2005; Jiang et 
al., 2005; Herault et al., 2005; Tayama et al., 2006b; Zheng et al., 2007a; Zheng et al., 2007b; 
Zheng et al., 2008b; Moyers et al., 2008a; Zacharatou Jarlskog et al., 2008; Taddei et al., 2008; 
Fontenot et al., 2008; Fontenot et al., 2009; Newhauser et al., 2009a; Taddei et al., 2009b; 
Bednarz et al., 2009; Fontenot et al., 2010; Zhang et al., 2010; Taddei et al., 2010a; Taddei et 
al., 2010b; Taddei et al., 2010c). The Monte Carlo code MCNPX (Monte Carlo N Particle 
eXtended) (Waters et al., 2007; Pelowitz, 2007) has been used extensively by our research 
group (Newhauser et al., 2007b) and was chosen for this work. 
 Monte Carlo simulations were completed to estimate the stray neutron dose for the proton 
arc therapy treatment plan for the medium patient. The process is reviewed here, and further 
details can be found in the literature (Newhauser et al., 2007b; Fontenot et al., 2008; Zheng et 
al., 2008a; Fontenot, 2008). We used an in-house code that converts patient CT and other 
treatment plan information into MCNPX input files, runs MCNPX simulations with version 
2.7c of the code, then converts the output into Digital Imaging and Communications in 
Medicine (DICOM) files that can be re-imported into the TPS for visualization and analysis. 
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For these simulations, the entire proton nozzle was simulated (Newhauser et al., 2007a), and 
the patient CT dataset was used as the voxelized phantom on which the dose was calculated 
using F6 tallies. Once the simulated dose distributions were re-imported in to the TPS, mean 
neutron doses to the bladder wall and rectal wall were computed and recorded.   
 Because neutrons have a different RBE for carcinogenesis than photons, a radiation 
weighting factor must be applied to convert absorbed dose to equivalent dose. The equation 
describing the relationship between absorbed dose and equivalent dose is 
                                                                   DwH R ,                                                     (2.1) 
where H is the equivalent dose, Rw  is the radiation weighting factor for neutrons, and D is the 
absorbed dose. Publication 92 of the International Commission on Radiological Protection 
(ICRP) (2003) recommends a continuous function for the weighting factor of neutrons based on 
neutron energy (Figure 2.6), with a maximum of approximately 20 at 1 MeV.  
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Figure 2.6 - Radiation weighting factor (wR) for neutrons vs. neutron energy (reprinted with 
permission) (ICRP, 2003).  
 Because the neutron spectra incident upon each organ are unique, Rw  values are also 
unique to each organ. These were determined by Fontenot et al. (2008; 2008; 2009) for a 
parallel-opposed proton therapy treatment of the prostate (Table 2.8) for the same three patients 
as studied in this work. In order to be conservative, the largest values of Rw  of the three 
patients were used for all three patients in our study. Because of the uncertainty in determining 
Rw  values (Kellerer et al., 2006; Hall, 2007; Fontenot, 2008; Fontenot et al., 2010), factors of 
0.5, 2, and 5 were applied to the ICRP values for sensitivity analyses (Table 2.8), where a value 
of 5 corresponds to a maximum neutron radiation weighting factor of approximately 100. The 
sensitivity of risk predictions to uncertainty in the radiation weighting factor was evaluated 
using the medium patient‟s nominal treatment plan.  
Table 2.8 – Mean neutron radiation weighting factors for the bladder and rectum for a parallel-
opposed proton therapy treatment of the prostate determined in the work of Fontenot et al. 
(2008; 2008; 2009). For sensitivity analysis, the Rw  values were modulated by factors of 0.5, 2 
and 5. 
Organ 
Rw  0.5* Rw  2* Rw  5* Rw  
Bladder 7.36 3.68 14.72 36.80 
Rectum  6.94 3.47 13.88 34.70 
  
 Then, the total equivalent dose for each dose-bin of the bladder wall and rectal wall from 
a proton therapy treatment for prostate cancer was found with the equation 
                                                  strayabsorbedtotal 1.1 HDH                                             (2.2) 
where Htotal is equal to the total equivalent dose in sieverts for the dose-bin, 1.1 is the 
recommended generic RBE value for protons (section 1.2.2) to convert to Gy (RBE), Dabsorbed is 
the absorbed therapeutic proton dose in gray, and Hstray is the stray equivalent dose (equation 
2.1). 
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 The stray doses for the small and large patients in this study were approximated as the stray 
doses estimated by Fontenot et al (2008) using MCNPX. In their study, the stray dose from 
parallel-opposed beam proton therapy was simulated for the same prostate cancer patients as 
used in this work. The total stray dose from parallel-opposed beam proton therapy of the 
prostate apparently provides a conservative estimate of the total stray dose from proton arc 
therapy of the prostate (Sengbusch et al., 2009). Neutron production increases as proton energy 
increases (Zheng et al., 2008a) and the highest beam energies in a proton arc therapy treatment 
plan occur at the lateral angles. Therefore, the lower energy protons from other angles produce 
fewer neutrons and contribute to a lower overall stray dose. However, the beam arrangement is 
uniformly distributed around the patient for our study, which could produce a different 
distribution of neutrons throughout the body. Despite the discrepancies in the beam 
arrangement, this was determined to be a reasonable estimate of neutron dose for this study.  
2.4. Risk Prediction 
 Unlike previous studies (Taddei et al., 2008; Fontenot et al., 2009), the risk to the bladder 
and rectum were found using organ wall contours instead of the conventional whole organ 
contour, including contents. The motivation behind our choice is that the contents of those 
organs will be excreted from the body and therefore do not have carcinogenic capabilities. 
Consequently, for detailed dosimetric studies predicting carcinogenic risk, it naturally follows 
to delineate organs as solely the organ tissue and to exclude the contents.  
 2.4.1. Linear-No-Threshold Risk Model 
 The BEIR VII report (NRC, 2006) provides a method for predicting risk of radiogenic 
cancers and assumes an LNT relationship of risk of second cancer and dose. The quantity of 
excess relative risk (ERR) was chosen as the metric to express the risk of incidence of an SMN 
for this work. ERR is defined as 
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                                                         1
unexposed
exposed
R
R
ERR ,                                                  (2.3) 
where Rexposed is the rate of the exposed population, Runexposed is the rate of the unexposed 
population. The risk coefficient of 
H
ERR
 (Sv
-1
) is calculated with the following equation: 
                                                 
60
* ae
H
ERR e
M ,                                             (2.4) 
where e* is equal to the age at exposure in years minus 30 when the age at exposure is less than 
30 years and equal to zero when the age at exposure is greater than 30 years; a is attained age 
(years); M  is the age-specific, and organ-specific instantaneous ERR/Sv value for males; γ 
accounts for the per-decade increase in age at exposure over the range of zero to 30 years, and 
η represents the exponent of attained age (NRC, 2006). From the information in BEIR VII and 
equation 2.4, risk coefficients were derived to be 0.51 ERR/Sv for the colon and 0.40 ERR/Sv 
for the bladder for the three patients studied (Fontenot, 2008). In addition, to separate the 
rectum from the colon, relative mass-fractions from Publication 89 of the ICRP (2002) were 
applied; 0.2 for the rectum and 0.8 for the colon.  
 Then, the ERR for each dose-bin, i, from the differential DVH was found by applying the 
risk coefficient to the equivalent dose of each dose-bin,                 
        ,
TTT
subregion
T
H
ERR
H
V
V
m
m
ERR i
i
i
                                     (2.5) 
where 
T
subregion
m
m
 is the fractional mass of the subregion compared to the total mass of the organ 
(0.2 for the rectum, 1 for the bladder), Vi  is the volume of the dose-bin (cm
3
), VT is total the 
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volume of the tissue (cm
3
), Hi  is the total equivalent dose (Sv) of the dose-bin, and 
TH
ERR
 is 
the tissue-specific risk coefficient derived from the equation 2.4 above (Sv
-1
).  
 Next, the 
i
ERRT  was summed over n dose-bins to find the ERR for a given tissue: 
 
                                                      
n
i
i
ERRERR
1
TT .                                                 (2.6) 
 It should also be noted that, for the LNT model, multiplying the risk coefficient by the 
tissue mean equivalent dose is the same as equation and 2.6 because of the linear relationship 
of risk and dose. This concept is described mathematically in equation 2.7, 
                
n
i
i
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ERR
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m
ERRERR
1 T
T
T
subregion
TT ,                                (2.7) 
where, HT is the mean equivalent dose of the tissue.  
 Finally, the total ERR for the patient was obtained from the sum over m tissue ERRs (m=2 
for our study: bladder and rectum), 
                                                         
m
j
j
ERRERR
1
T .                                                   (2.8) 
 Once the ERR was determined (regardless of risk model), the ratio of excess relative risk 
(RRR) was calculated by 
                                                          
VMAT
ProtonArc
ERR
ERR
RRR .                                                  (2.9)  
According to this definition, an RRR less than one indicates a lower risk of an SMN following 
proton arc therapy and an RRR greater than one indicates a lower risk of an SMN following 
VMAT.                        
 2.4.2. Alternate High Dose Risk Models 
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 The LNT relationship of the BEIR VII report is appropriate to predict radiogenic cancer 
risk for low doses up to a few sieverts (NCRP, 1993; Hall and Wuu, 2003; NRC, 2006), but the 
relationship between dose and risk is less well understood at higher doses. As discussed in 
section 1.3 and following the approach of Fontenot et al. (2008; 2009), the linear-exponential 
and linear-plateau models are proposed alternatives to the LNT model that account for cell 
sterilization. These models decrease or plateau, respectively, beyond a given equivalent dose 
which ranges from approximately 10 Sv to 40 Sv in the literature. The forms of the alternate 
risk models were similar to the work by Schneider et al. (2005; 2006; 2007) and were 
generated and applied by Fontenot et al. (2008; 2009). Both dose levels for inflection of the 
risk models were investigated in this work and will be denoted as the name of the risk model 
with a “-10” or “-40” suffix, e.g., “linear-exponential-10”. 
 The linear-exponential model of ERR for a dose-bin (ERRT)i was calculated with the 
equation, 
                                    i
H
i
i
i
eH
H
ERR
V
V
m
m
ERR T
0
TTT
subregion
T ,                          (2.10) 
where 
0
TH
ERR
 is the organ-specific LNT risk model from BEIR-VII, Hi is the tissue-specific 
equivalent dose for the dose-bin, and αT is the tissue specific parameter that accounts for cell 
sterilization. Likewise, the linear-plateau excess relative risk for a dose-bin is given by 
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Hi
i
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V
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T ,                       (2.11) 
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where the variables correspond to those in equation 2.10. The values for 
0
TH
ERR
 and αT for 
the bladder and rectum were computed by Fontenot et al. (2008) and are listed in Table 2.9, 
below. 
Table 2.9 - Risk model parameters for the linear-exponential and linear-plateau models for the 
bladder and rectum in Sv
-1
 (Fontenot, 2008). 
 
Risk Model 
Bladder Rectum 
0
TH
ERR
 αT 
0
TH
ERR
 αT 
Linear-exponential-10 0.49 0.090 0.61 0.090 
Linear-exponential-40 0.46 0.025 0.57 0.025 
Linear-plateau-10 0.51 0.250 0.65 0.250 
Linear-plateau-40 0.47 0.068 0.58 0.068 
 
 Then, the RRRs for the linear-exponential and linear-plateau models were found using the 
same method as for the LNT model. First the ERRdb was summed over all dose-bins (equation 
2.6), then the ERRT was summed over all tissues (equation 2.8), and finally the RRR was found 
by taking the ratio of the ERRProtonArc to ERRVMAT (equation 2.9).  
 To illustrate the behavior of risk as a function of dose, Figures 2.7 and 2.8 plot the predicted 
risk for incidence of SMN in the bladder and rectum, respectively.  
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Figure 2.7 - The LNT, linear-exponential, and linear-plateau risk models used to predict ERR 
of SMN incidence of the bladder (Fontenot et al., 2009). Volume-weighting for the fractional 
volume of a specific dose-bin, 
TV
Vi , has been set to 1 for this figure.  
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Figure 2.8 - The LNT, linear-exponential, and linear-plateau risk models used to predict ERR 
of SMN incidence of the rectum (Fontenot et al., 2009). Volume-weighting for the fractional 
volume of a specific dose-bin, 
TV
Vi , has been set to 1 for this figure.  It can be seen that, 
partially due to the 0.2 mass-weight for the rectum, the ERR per Sv is less for the rectum than 
for the bladder. 
 
 2.4.3. Example Risk Calculations 
 To clarify the process of risk calculation, an example for both the LNT and an alternate risk 
model are provided below. First, the risk of an SMN of the bladder (wall) for the medium 
patient following VMAT was found using the LNT model. In this case, the mean dose to the 
bladder wall was 16.8 Sv (see sections 3.1.1 and 3.2.1), and the organ-specific, patient-specific 
risk coefficient for the bladder was 0.4 Sv
-1
 (section 2.4.1). Therefore, following equation 2.7, 
the LNT ERR for the bladder was given by 
                                                     7.64.08.16 1SvSv .                                             (2.12) 
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  The second example calculation, shown below, describes the prediction of the risk of 
SMN incidence in the rectum (wall) for the medium patient following proton arc therapy for 
the linear-exponential-10 risk model. The differential DVH for the tissue of interest was 
required for this calculation, and was exported from the treatment planning system into a 
spreadsheet. A graph of the differential DVH for the rectal wall was shown below in dark blue 
in Figure 2.9. After the differential DVH was obtained, the stray dose was added to every dose-
bin. Then, equation 2.10 was applied to each dose-bin to obtain the differential excess relative 
risk contributed by each dose-bin (Figure 2.9).  
 
Figure 2.9 - Calculated differential DVH and (ERRT)i for the rectum for the nominal proton arc 
therapy plan for the medium patient.  
 
Finally, the differential risks were summed to yield the total risk for the tissue. Combining 
equations 2.6 and 2.10, this process can be expressed as 
                              19.061.0
33
2.0
1
09.0
T
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i
i
ieH
V
ERR ,                           (2.13) 
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where the sum was over all dose-bins, the 0.2 weighting factor is the 
T
subregion
m
m
 for the rectum, 
Vi  is the volume of the dose-bin in cm
3
, 33 is the VT of the rectal wall in cm
3
, 0.61 is the 
0
TH
ERR
for the linear-exponential-10 model for the rectum (Sv
-1
), Hi  is the equivalent dose for 
the dose-bin (Sv), and 0.09 is αT for the rectum (Sv
-1
) (Table 2.9).  
 
 2.4.4. Statistical Analysis 
 Due to time constraints on the length of this thesis project, the sample size for this work 
was limited to three patients. Despite the limited sample size, two statistical tests were chosen 
to compare the proton arc therapy and VMAT risk estimates: the sign test and the t-test 
(Rosner, 2006). The objectives of the tests in this work were mainly educational. However, 
these tests would be appropriate for a larger sample size, e.g., a future work. The software 
package StatXact® version 7.0 from Cytel Studio (Cambridge, MA) was used for both 
statistical tests. 
 The sign test is a nonparametric test that determines whether two samples are from the 
same distribution but ignores the magnitude of the differences, which makes it insensitive to 
outliers. Because of the small sample size, the exact sign test was performed. For our purposes, 
the quantity of interest was RRR and the value of interest was one (meaning equal risk 
following proton arc therapy and VMAT), and each RRR was defined as “+” if it was greater 
than one and “–“ if was less than one. The null hypothesis was H0: P(+) ≥ P(–) and the alternate 
hypothesis was H1: P(+) < P(–), where P(±) is the probability of a + or –, respectively. The test 
statistic T is found, which is the total number of –‟s (RRR < 1). Then, n was defined to be the 
total number of +‟s and –‟s, excluding ties. Next, t is found using the equation 
                                                           2
1
2
1
nwnt ,                                               (2.14) 
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where wα is the 95
th
 percentile of the w distribution for a one-sided significance level (α) of 
0.05 (α is also the probability of a falsely rejecting the null hypothesis). Finally, H0 was 
rejected at the level of α if T is greater than or equal to n-t (Conover, 1980). 
 The t-test is a parametric test that determines whether the mean of a sample distribution is 
the same as the population mean. It should be noted that the t-test assumes a t-distribution for 
the sample mean, which may not be assumable for a sample size of three, given the underlying 
distribution of ERR. Regardless of the small sample size, it was decided that performing the t-
test was of pedagogical value. In this case, to test null hypothesis H0: RRR ≥ 1 vs. the alternate 
hypothesis:  H1: RRR < 1, with a one-sided significance level α of 0.05, the test statistic t was 
computed (Rosner, 2006) according to 
                                                                   
n
s
x
t 0 ,                                                     (2.15) 
where x is the sample mean (RRR), μ0 is the expected or population mean (1), s is the sample 
standard deviation, and n is the sample size. The null hypothesis was rejected if t < tn-1,1-α, 
where tn-1,1-α is the 5
th
 percentile of the t distribution with n-1 degrees of freedom for a one-
sided test. 
 2.4.5. Uncertainty Analysis 
 In order to estimate the uncertainty associated with the prediction of the mean RRR, error 
propagation was performed. A derivation of the formula for uncertainty in RRR for a patient 
was reported by Fontenot et al. (2008; 2010) and was adapted for this work. One of the 
differences in our formula is that the uncertainty in therapeutic and stray dose for VMAT 
(analogous to IMRT in the work of Fontenot et al.) was combined into one factor due the 
method utilized for stray dose estimation. Another difference is that there is a term for the 
uncertainty in the Rw  added in quadrature. Additionally, our error propagation is explicitly for 
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the mean RRR, in order to incorporate the covariance from the correlations between the 
modalities.  Finally, it was found that the uncertainty in risk model was asymmetric when the 
LNT model was assumed as the baseline risk model. Therefore, a term for uncertainty in the 
risk model was added in quadrature, but only to the negative side. This resulted in an 
asymmetrical overall relative uncertainty in the mean RRR:       
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In this formula, 
RRR
RRR  is the relative uncertainty in the mean RRR, and the quantity σ 
represents one standard deviation (therefore a 68% confidence interval). The outermost sum is 
over the 3 patients (p), and the inner sums are over the two tissues (T) - the bladder and the 
rectum. The subscript V denotes VMAT and the subscript P denotes proton arc therapy. 1ERR  
   
 47 
is the excess relative risk from primary radiation, 
1
1
D
D
 is the relative uncertainty in the 
therapeutic dose from the treatment planning system for proton arc therapy and the total 
uncertainty in the VMAT dose, 2ERR is the excess relative risk from the stray radiation, 
2
2
D
D
 is the relative uncertainty in the stray dose, and TERR  is the total excess relative risk 
for a given tissue. The 
1
1
D
D
 from the VMAT plan was estimated using the quadratic sum of 
the relative uncertainty in the therapeutic dose from the treatment planning system and the 
uncertainty in the stray dose correction method (section 3.2.1). The two terms 
Rw
RRR
RRR
and 
RM
RRR
RRR
are the relative uncertainty in the mean RRR contributed from the uncertainty in the 
Rw  and risk model, respectively. Both of these quantities were determined with a sensitivity 
analysis to evaluate their effect on RRR, which is why they are relative to RRR and added in 
quadrature to the rest of the equation. 
Rw
RRR
RRR
 was estimated by assuming the 95% 
confidence interval of the Rw  was 0.5* Rw  to 5* Rw  (Table 2.8) for each patient and dividing 
the range in resulting mean RRR by 2 to find 2σ. Then, 2σ was divided by 2 to obtain the 
numerator in the uncertainty term. 
RM
RRR
RRR
 only contributed to the negative overall 
uncertainty term (2.16b). This term was also found with a sensitivity analysis, where the range 
in mean RRR values from the risk models studied in this work was assumed to be one σ of the 
distribution of RRR from uncertainty in the risk model. The last term accounts for the 
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covariance, which, in this case, reduces the relative uncertainty in the mean RRR because 
correlations in the error of the terms used in the calculation of the mean RRR. The covariance 
was calculated using the equation: 
                        i
i
i
iPV
PP
n
i
VVERRERR ERRERRERRERR
n 1
1
,                     (2.17) 
where n is the number of patients (3 for this study), and ERR  denotes the mean value (Taylor, 
1982).  
 In addition to propagating the uncertainty for the mean RRR, the uncertainty was 
propagated for two specific cases. First, the uncertainty was propagated for each patient 
individually according to the equations: 
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                      (2.18b) 
where the variables correspond to equations 2.16a and 2.16b, but are for each patient instead of 
the mean. Second, the uncertainty was propagated for the mean RRR (according to equations 
2.16a and 2.16b) without the 
2
Rw
RRR
RRR
and the covariance term. 
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 2.4.6. Summary of Risk Calculations 
 In order to clarify and summarize the methods for this work, the various combinations of 
variables studied are organized below in Tables 2.10 and 2.11. 
Table 2.10 - Summary of variables and their corresponding specific aim. 
Goal 
Patient 
Model 
Risk Model 
Modality 
Studied 
Proton 
Arc Beam 
Weighting 
Spec. 
Aim 
Baseline 
LNT RRR 
Estimate 
Small Linear-no-threshold 
VMAT and 
Proton Arc 
Uniform 1 Medium Linear-no-threshold 
Large Linear-no-threshold 
Sensitivity of 
RRR to Risk 
Model 
Small, 
Med, and 
Large 
Linear-exponential-10 
VMAT and 
Proton Arc 
Uniform 1 
Small, 
Med, and 
Large 
Linear-exponential-40 
Small, 
Med, and 
Large 
Linear-plateau-10 
Small, 
Med, and 
Large 
Linear-plateau-40 
Sensitivity of 
RRR to 
Neutron Rw  
Medium Linear-no-threshold Proton Arc Uniform 1 
Sensitivity of 
RRR to 
Beam 
Weighting 
Medium Linear-no-threshold Proton Arc 
 
Non-
uniform 
2 
Sensitivity of 
RRR to 
Margin Size 
Medium 
Linear-no-threshold 
VMAT and 
Proton Arc 
Uniform 3 
Linear-exponential-10 
Linear-exponential-40 
Linear-plateau-10 
Linear-plateau-40 
 
Table 2.11 - Summary of the source of stray doses for the proton arc therapy treatment plans. 
Patient Model Specific Aim 
Source of Neutron Dose 
Estimate 
Small 1 Fontenot et al. (2008) 
Medium 1, 2 and 3 Simulations from this work 
Large 1 Fontenot et al. (2008) 
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Chapter 3 
Results 
 The results from this work are presented in this chapter. First, the treatment plans and 
therapeutic dose determination will be presented (section 3.1). Specifically, details of the 
VMAT (section 3.1.1) and proton arc (section 3.1.2) treatment plans are presented, followed by 
dose-volume histogram comparisons in section 3.1.3. Next, the results of the stray dose 
determination are presented (section 3.2). Finally, section 3.3 presents the predicted ERR values 
for VMAT and proton arc therapy, the RRR of the two modalities, the statistical analysis 
(section 3.3.1), and the uncertainty analysis (section 3.3.2).  
3.1. Therapeutic Dose Distributions 
 3.1.1. Volumetric Modulated Arc Therapy 
 The VMAT treatment plans created for specific aim 1 are presented below. Figure 3.1 
shows the therapeutic dose using a colorwash scale ranging from 10 Gy (blue) to 80 Gy (red). 
The prescribed dose for each patient was 76 Gy (normalized to 78.8 Gy to the mean of the 
PTV; section 2.2.1), and the MUs required for the small, medium and large patients‟ treatment 
plans were 669, 962, and 920, respectively. For the small patient, the maximum dose was 
located in the PTV in the right seminal vesicle and was 107.9%. The maximum dose for the 
medium patient was located in the left, inferior, posterior portion of the PTV and was 108.8%. 
For the large patient, the maximum dose was located in the PTV in the left seminal vesicle and 
was 108.0%. The minimum, mean, and maximum doses to the CTV, PTV, rectum (and 
contents), rectal wall, bladder (and contents), and bladder wall for these treatment plans are 
presented in Table 3.1, below. In general, the low dose was distributed over a large amount of 
healthy tissue, but the high dose was conformed to the PTV. A high dose gradient existed in the 
rectum, which was desirable to minimize toxicities and satisfy the DVH constraints (Table 2.2).  
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Figure 3.1 - Axial (left) and sagittal (right) CT slices of the small (top), medium (middle), and 
large (bottom) patients‟ VMAT treatment plans showing a colorwash of the dose distribution 
from 10 Gy to 80 Gy. The CTV is shown in cyan, the PTV in white, the bladder in yellow, and 
the rectum in green. The 30 Gy isodose level is represented by cyan. 
 
 
Table 3.1 - Minimum, mean, and maximum therapeutic doses for the CTV, PTV, rectum and 
contents, rectal wall, bladder and contents, and bladder wall for the small, medium, and large 
patients for the VMAT treatment plans with nominal margins for specific aim 1. 
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 The VMAT treatment plans created for specific aim 3 with various size margins around 
the CTV are shown below in Figure 3.2. It can be seen that as the margins from the CTV 
increase, the high-dose area (red) increases to cover the larger PTV and the medium dose (30 
Gy) (cyan) extends further into the rectum. The effect of margin size on dose to the bladder 
wall and rectal wall is presented in Table 3.2 and graphed in Figure 3.3 below, where it can be 
seen that mean doses to the bladder wall and rectal wall increase as margin size increases.
 However, maximum and minimum doses remain relatively constant with increasing 
margin size. This is because the bladder wall and rectal wall are already receiving very close to 
the maximum dose for the plan. Therefore, as the high dose encroaches further into the organs, 
the mean dose increases while the maximum dose remains fairly stable. Similarly, the 
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minimum dose to the organs remains relatively constant because it is determined by the dose 
far from the target, which is not significantly affected by the size of the high dose region.   
 
Figure 3.2 – Axial images of a sampling of the VMAT treatment plans with varying margin 
size around the CTV. Plan indices correspond to those in Table 2.3, where the margins increase 
as the plan index increases. The CTV is shown in cyan, the PTV in white, and the rectum in 
green. Close-up views of the central region including the CTV, PTV and rectum are inset. 
 
Table 3.2 - Minimum, mean and maximum doses to the bladder wall and rectal wall for VMAT 
as a function of margin size around the CTV. Plan indices correspond to Table 2.3, where plan 
1 has the smallest expansion and plan 6 has the largest expansion. As expected, mean doses to 
both the bladder wall and rectal wall increase as margin size increases. 
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Figure 3.3 – Therapeutic mean absorbed dose to the bladder wall and rectal wall as a function 
of “else” margin size around the CTV to create the PTV for the VMAT treatment plans for 
specific aim 3. Posterior margins are 2 mm less than those graphed, except for 0 mm “else” 
expansion, where the posterior margin is also 0 mm. Margin sizes correspond to Table 2.3. The 
nominal expansion is 7 mm in the “else” anatomical directions. As expected, mean dose 
increases with margin size. 
 
 3.1.2 Proton Arc Therapy 
 The proton arc therapy treatment plans with varying number of treatment beams are 
presented below. The mean doses to the bladder (and contents), bladder wall, rectum (and 
contents), rectal wall, femoral heads, and normal tissues were plotted vs. the number of 
treatment beams. Figure 3.4 demonstrates the weak dependence of mean dose on number of 
beams beyond 8 beams. The risk of second cancer of the bladder and rectum was also 
calculated for these treatment plans (method described in section 2.4), which also shows a weak 
dependence on number of beams (Figure 3.5). Because of the smooth shape of the isodose lines 
produced with the 16-field plan (Figure 3.6), we approximated all arc dose distributions using 
16 static fields.  
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Figure 3.4 – Calculated mean dose (DT) vs. the number of equally spaced and uniformly 
weighted treatment beams (n). Little variation is observed beyond 8 beams. 
 
 
Figure 3.5 – Predicted excess relative risk (ERR) of a second malignant neoplasm in the 
bladder and rectum vs. number of equally spaced and uniformly weighted beam angles, n, for 
two different risk models. The linear-no-threshold (LNT) model is the least dependent on the 
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distribution of dose in a volume, and the linear-exponential-10 (Lexp10) is the most dependent 
on the distribution of dose. A weak dependence on the number of beams was observed.  
 
 
Figure 3.6 - Isodose lines of the 6, 8, 12, and 16-beam treatment plans, showing the 45 Gy 
(RBE) (orange), 30 Gy (RBE) (cyan), and 20 Gy (RBE) (yellow) isodose lines, revealing a 
significant smoothing with increasing number of beams. 16 beams produced extremely smooth 
isodose lines. The CTV is shown in cyan, the PTV in white, and the rectum in green. 
 
 The proton arc therapy treatment plans created for specific aim 1 are presented below. 
Figure 3.7 shows the therapeutic dose using a colorwash scale ranging from 10 Gy (RBE) to 80 
Gy (RBE). For the small patient, the maximum dose was located in the PTV in the seminal 
vesicles and was 106.6%. The maximum dose to the medium patient was in the PTV in the 
bladder wall and was 105.5%. For the large patient, the maximum dose was within the CTV 
and was 105.6%. The minimum, mean, and maximum doses to the CTV, PTV, rectum (and 
contents), rectal wall, bladder (and contents), and bladder wall for these treatment plans are 
presented in Table 3.3, below. It can be seen that the low dose region encompasses a smaller 
overall volume than the VMAT plans (Figure 3.1). On average, proton arc therapy reduced the 
volume of normal tissue exposed to doses between 10 and 30 Gy or Gy (RBE) by 73%. The 
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high dose region is very conformal, but because proton treatment beams are typically designed 
with larger margins, the high dose region is slightly larger in the proton arc therapy plans than 
in the VMAT plans. Specifically, the small, medium, and large patients‟ irradiated volumes 
(volume receiving at least 76 Gy or Gy (RBE)) were 106, 156 and 159 cm
3
, respectively, for 
proton arc therapy, and 89, 138 and 135 cm
3
, respectively, for VMAT. 
 
 
Figure 3.7 - Axial (left) and sagittal (right) CT images of the small (top), medium (middle), 
and large (bottom) patients‟ proton arc treatment plans showing a colorwash of the dose 
distribution from 10 Gy (RBE) to 80 Gy (RBE). The CTV is shown in cyan, the PTV in white, 
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the bladder in yellow, and the rectum in green. The 30 Gy (RBE) isodose level is represented 
by cyan. 
 
 
Table 3.3 - Minimum, mean, and maximum therapeutic doses for the CTV, PTV, rectum and 
contents, rectal wall, bladder and contents, and bladder wall for the small, medium, and large 
patient for the proton arc therapy treatment plans with uniform beam weighting and nominal 
margins for specific aim 1. 
 
 
 The first set of proton arc therapy treatment plans created using non-uniform beam weights 
(specific aim 2) is shown below in Figure 3.8 (optimization objectives 1, 2, and 3 from Table 
2.5, respectively). The beam angles found through optimization to minimize the combined risk 
of second cancer of the bladder and rectum were 90 and 270 degrees, a 2-field lateral-opposed 
treatment with equal beam weighting. The beam angles that minimized the risk of second 
cancer of the bladder only were posterior oblique beams at 157.5 and 202.5 degrees with equal 
weighting. The beam angles that minimized the risk of second cancer of the rectum only were 
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anterior oblique beams at 45 and 315 degrees with equal weighting. The minimum, mean, and 
maximum doses to the bladder wall and rectal wall from these treatment plans are listed in 
Table 3.4.  
 
Figure 3.8 - Proton arc therapy treatment plans with SMN risk-minimized beam weighting for 
combined bladder and rectum (A, 90 and 270 degrees with 1:1 weighting), bladder only (B, 
157.5 and 202.5 degrees with 1:1 weighting), and rectum only (C, 45 and 315 degrees with 1:1 
weighting).  
 
 Another goal of specific aim 2 was to determine the optimal beam weighting for a patient 
with a prosthetic hip (objective 4 from Table 2.5). The resulting treatment plans are shown in 
Figure 3.9 below. The plan labeled “prosthetic hip plan 1” utilized 270 and 292.5 degree beams 
with weighting of 1.94:1, respectively. This plan minimized the risk of SMN incidence in the 
bladder and rectum, but deposited an unacceptable amount of dose in the healthy femoral head: 
15% of the right femoral head received at least 64.8 Gy (RBE). The clinical objective for the 
femoral heads is that 15% of the structure should receive no more than 45 Gy (RBE). A second 
treatment plan, “prosthetic hip plan 2”, shown on the right in Figure 3.9) utilized 270 and 157.5 
degree beams with weighting of 1.94:1, respectively, and met the clinical DVH constraints for 
the femoral head, bladder, and rectum. The minimum, mean, and maximum doses to the 
bladder wall, rectal wall, and femoral head from these treatment plans are listed in Table 3.4.     
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Figure 3.9 - Proton arc therapy treatment plans with SMN risk-minimized beam weighting for 
combined bladder and rectum with a prosthetic hip. The figure on the left shows “Prosthetic 
Hip Plan 1”, with the angles of 270 and 292.5 degrees and weights of 1.94:1, respectively. The 
figure on the right shows “Prosthetic Hip Plan 2”, with angles of 270 and 157.5 degrees and 
weights of 1.94:1, respectively. Notice the reduction in high dose to the right femoral head in 
prosthetic hip plan 2. 
 
Table 3.4 - Minimum, mean and maximum doses to the bladder wall and rectal wall from 
various risk-optimized proton arc therapy treatment plans.  
 
 
 The proton arc therapy treatment plans with varying margins created for specific aim 3 
are shown below in Figure 3.10. Similar to the VMAT plans, as the margins from the CTV 
increase, the red high-dose region increases to cover the larger PTV and the cyan region of 
medium dose (30 Gy (RBE)) extends further into the rectum. The dose to the bladder wall and 
rectal wall are presented for each treatment plan in Table 3.5 and graphed in Figure 3.11 below, 
where it can be seen that doses to the bladder wall and rectal wall increase as margin size 
increases. Similar to the VMAT plans for specific aim 3, the minimum and maximum doses to 
the bladder wall and rectal wall are relatively insensitive to margin size (section 3.1.1). 
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Figure 3.10 – Axial CT images of a sample of the proton arc treatment plans with varying 
margins from the CTV. Plan indices correspond to Tables 2.6 and 2.7, where the margins 
increase with plan index. The margins listed on the figure correspond to the margins from the 
CTV to create the PTV. Lateral, distal and proximal margins around the CTV can be found in 
Tables 2.6 and 2.7. The CTV is shown in cyan, the PTV in white, and the rectum in green. The 
colorwash scale is from 10 Gy (RBE) to 80 Gy (RBE). Close-up views of the central region 
including the CTV, PTV and rectum are inset. 
 
Table 3.5 - Minimum, mean and maximum doses to the bladder wall and rectal wall for proton 
arc therapy as a function of margin size around the CTV. Plan indices correspond to Tables 2.6 
and 2.7, where plan 1 has the smallest margin and plan 6 has the largest margin. 
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Figure 3.11 – Therapeutic mean dose to the bladder wall and rectal wall as a function of “else” 
margin size around the CTV to created the PTV for the proton arc therapy treatment plans for 
specific aim 3. Posterior margins are 2 mm less than those graphed, except for the 0 mm “else” 
expansion, where the posterior margin is also 0 mm. Plan indices and margin sizes correspond 
to Tables 2.6 and 2.7. The nominal expansion is 7 mm “else.” As expected, dose increased with 
margin size. 
  
 3.1.3. Dose-Volume Histogram Comparisons 
 Since DVHs are traditionally plotted for the whole organ (including the contents), we 
plotted the difference between the traditional whole organ contour and the organ wall contour 
in Figures 3.12 and 3.13, below. In general, the organ wall curves are slightly higher, indicating 
a larger percentage of the organ receiving a given dose. 
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Figure 3.12 - Cumulative dose-volume histogram for the medium patient for VMAT (black; 
Gy) and uniformly weighted proton arc therapy (red; Gy (RBE)) nominal treatment plans 
created for specific aim 1 showing the difference between therapeutic absorbed dose to the 
bladder (and contents) and bladder wall. The bladder wall curves are consistently higher than 
the bladder curves. 
 
 
 
Figure 3.13 - Cumulative dose-volume histogram for the medium patient for the VMAT 
(black; Gy) and uniformly weighted proton arc therapy (red; Gy (RBE)) nominal treatment 
plans created for specific aim 1 showing the difference between therapeutic absorbed dose to 
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the rectum (and contents) and rectal wall. In general, the rectal wall curves are higher than the 
rectum curves.  
 
 Figures 3.14 and 3.15 display the bladder wall and rectal wall DVHs, respectively, for the 
VMAT and proton arc therapy treatment plans created for specific aim 1. The results from all 
three patients are plotted together. The only obvious dependence on patient size is that the large 
patient doses are the highest in all cases. All of the DVH constraints were satisfied for all plans 
shown in Figures 3.14 and 3.15 and are quantitatively presented in Table 3.6.    
 
 
Figure 3.14 - Bladder wall cumulative dose-volume histogram for the small, medium, and 
large patients‟ nominal treatment plans for VMAT (black; Gy) and uniformly weighted proton 
arc therapy (red; Gy (RBE)) for specific aim 1.  
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Figure 3.15 - Rectal wall cumulative dose-volume histogram for the small, medium, and large 
patients‟ nominal treatment plans for VMAT (black; Gy) and uniformly weighted proton arc 
therapy (red; Gy (RBE)) for specific aim 1.  
 
Table 3.6 - DVH constraints and results for the bladder and rectum for the small, medium, and 
large patient treatment plans for specific aim 1 (uniformly weighted proton arc therapy). The 
results are shown for the bladder and rectum volumes (including contents) for consistency with 
clinically used DVH constraints. All DVH constraints were met.      
 
 
 For specific aim 2, treatment plans were created to investigate the effect of proton beam 
weighting on the risk of SMN incidence for proton arc therapy. Figures 3.16 through 3.20 
display the DVHs for the bladder wall and rectal wall for the various optimized proton arc 
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therapy plans compared to the nominal (uniformly weighted) proton arc therapy plan created 
for specific aim 1. Specifically, Figure 3.16 shows the resulting DVH from the risk-optimized 
plan where the combined risk of second cancer incidence of the bladder and rectum was 
minimized. Then, Figures 3.17 and 3.18 correspond to the treatment plans where the risk of 
second cancer of the bladder only and second rectal cancer only, respectively, were minimized. 
Finally, the DVHs for the treatment plans for the special case of a patient with a prosthetic hip 
are shown in Figures 3.19 (prosthetic hip plan 1) and 3.20 (prosthetic hip plan 2). The DVH for 
the right femoral head is also plotted for the prosthetic hip plans, since it is of particular 
concern. The quantitative DVH constraints and results for the bladder and rectum are listed in 
Table 3.7. All DVH constraints for the bladder and rectum were met, except for the rectal 
constraints shown in red for the bladder-only optimized treatment plan.   
 
 
Figure 3.16 - Cumulative dose-volume histogram for the SMN risk-minimized (bladder and 
rectum) beam weighted treatment plan (solid line) for the bladder wall (orange) and rectal wall 
(green) for proton arc therapy compared to the nominal equally-weighted treatment plan 
(dashed line). 
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Figure 3.17 - Cumulative dose-volume histogram for the SMN risk-minimized (bladder only) 
beam weighted treatment plan (solid line) for the bladder wall (orange) and rectal wall (green) 
for proton arc therapy compared to the nominal equally-weighted treatment plan (dashed line). 
 
 
Figure 3.18 - Cumulative dose-volume histogram for the SMN risk-minimized (rectum only) 
beam weighted treatment plan (solid line) for the bladder wall (orange) and rectal wall (green) 
for proton arc therapy compared to the nominal equally-weighted treatment plan (dashed line). 
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Figure 3.19 - Cumulative dose-volume histogram for the proton arc therapy prosthetic hip plan 
1 (solid line) and the nominal uniformly weighted proton arc therapy plan from specific aim 1 
(dashed line). The beam weighting was optimized to minimize the combined risk of second 
cancer of the bladder and rectum. 
 
 
Figure 3.20 - Cumulative dose-volume histogram for the proton arc therapy prosthetic hip plan 
2 (solid line) and the nominal uniformly weighted proton arc therapy plan from specific aim 1 
(dashed line). The beam weighting was optimized to minimize the combined risk of second 
cancer of the bladder and rectum. 
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Table 3.7 - DVH constraints and results for the bladder and rectum for the treatment plans 
created for specific aim 2 with non-uniform (risk-minimized) beam weighting. The results are 
shown for the bladder and rectum volumes (including contents) for consistency with traditional 
DVH constraints. All DVH constraints were met, except the rectal constraints shown in red for 
the bladder-only optimized plan (50%, 40% and 20% volume constraints).      
 
 
 Figures 3.21 through 3.24 show the cumulative DVHs for the treatment plans created for 
specific aim 3 where the margin size around the CTV was varied. The bladder wall and rectal 
wall DVHs are shown for the VMAT treatment plans in Figures 3.21 and 3.22, respectively, 
and the proton arc therapy treatment plans in Figures 3.23 and 3.24, respectively. It can be seen 
that the DVH curve is higher as the treatment margin increases, indicating a larger volume 
receiving a given dose. All of the DVH constraints used in the planning process were met for 
the VMAT and proton arc therapy plans and are listed in Tables 3.8 and 3.9, respectively.  
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Figure 3.21 - Cumulative dose-volume histogram for the bladder wall for the VMAT treatment 
plans for specific aim 3. The margin size around the CTV increased with plan index, revealing 
the positive relationship between volume irradiated and margin size. 
 
 
Figure 3.22 - Cumulative dose-volume histogram for the rectal wall for the VMAT treatment 
plans for specific aim 3. The margin around the CTV increased with plan index, revealing the 
positive relationship between volume irradiated and margin size. 
 
Table 3.8 - DVH constraints and results for the bladder and rectum for the VMAT treatment 
plans with varying margin size. The results are shown for the bladder and rectum volumes 
(including contents) for consistency with traditional DVH constraints. All DVH constraints 
were met. In general, dose increased with plan index (and margin size).      
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Figure 3.23 - Cumulative dose-volume histogram for the bladder wall for the uniformly 
weighted proton arc therapy treatment plans for specific aim 3. The margin size around the 
CTV increased with plan index, revealing the positive relationship between volume irradiated 
and margin size. 
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Figure 3.24 - Cumulative dose-volume histogram for the rectal wall for the uniformly weighted 
proton arc therapy treatment plans for specific aim 3. The margin around the CTV increased 
with plan index, revealing the positive relationship between volume irradiated and margin size. 
 
Table 3.9 - DVH constraints and results for the bladder and rectum for the proton arc therapy 
treatment plans with varying margin size. The results are shown for the bladder and rectum 
volumes (including contents) for consistency with traditional DVH constraints. All DVH 
constraints were met. In general, dose increased with plan index (and margin size) increases.      
 
 
3.2 Stray Dose Determination 
 3.2.1 Volumetric Modulated Arc Therapy Stray Dose 
  The contribution of stray dose (from leakage and scatter photons) for the VMAT 
treatment plans was estimated by introducing a correction to out-of-field region (outside the 5% 
isodose surface calculated by the TPS) where the TPS underestimates stray radiation (Howell et 
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al., 2010a; Howell et al., 2010b). The nominal correction was defined as a 40% increase 
applied to the out-of-field dose portion differential DVH for the bladder wall and rectal wall. 
The effect of this stray dose estimation is shown in Table 3.10. The largest impact of the 40% 
increase on the mean dose was seen in the bladder wall of the medium patient: a difference of 
0.43 Gy. Additionally, the lower and upper bounds of the corrected mean dose were found by 
increasing the out-of-field dose by 20% and 60%, respectively (Howell et al., 2010a; Howell et 
al., 2010b). Then, the percent error in the corrected mean dose was found by dividing the 
difference in the upper bound and lower bound mean doses by two, dividing that by the 
nominally corrected mean dose, and multiplying by 100. The resulting errors in mean dose 
ranged from 0.1% to 1.3%, depending on the patient and the organ (see last row in Table 3.10). 
The nominal, corrected differential DVH was used for the risk calculations, described in 
section 3.3, and the maximum percent error was used in the uncertainty analysis, described in 
section 3.3.2.   
Table 3.10 - Effect of the stray dose estimation method on the mean dose of the bladder wall 
and rectal wall for each patient. The maximum difference between the nominal corrected value 
and the uncorrected value was seen in the bladder wall of the medium patient: a difference of 
0.43 Gy. The maximum percent error, 1.3%, was used in the uncertainty analysis described in 
sections 2.4.5 and 3.3.2.   
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 3.2.2 Proton Arc Therapy Stray Dose 
 The stray dose from proton arc therapy was calculated using Monte Carlo simulations for 
the medium patient and estimated from the literature (Fontenot, 2008; Fontenot et al., 2008) for 
the small and large patients. The calculated and estimated stray doses are listed below in Table 
3.11. The stray rectal dose calculated in this work for the medium patient was slightly higher 
than the estimated dose from the work of Fontenot et al., most likely due to the posterior 
component of the arc delivery, which was not accounted for in the estimations from the 
literature. Another difference in the methodology from the work of Fontenot et al. is that their 
values were obtained using 2 cm diameter receptors at the location of the organ in a phantom, 
where our work used the mean dose calculated from the organ wall DVH. 
 
Table 3.11 - Stray equivalent doses for the bladder and rectum (and therefore the bladder wall 
and rectal wall) for the small, medium and large patients for the whole proton arc therapy 
treatment calculated in MCNPX and estimated from Fontenot et al. (2008). 
Structure 
 
Small Patient 
Stray Dose [Sv] 
Medium Patient Stray Dose [Sv] 
Large Patient 
Stray Dose [Sv] 
Estimated from 
literature 
Estimated from 
literature 
Our  MCNPX 
calculations 
Estimate from 
literature 
Bladder 0.82 0.97 0.96 1.06 
Rectum 0.61 0.76 1.13 0.88 
 
3.3 Risk Prediction 
 The predicted risk of SMN incidence following VMAT and proton arc therapy for prostate 
cancer at the exposed age of 60 years and the attainted age of 70 years is presented below. 
Table 3.12 lists the predicted ERR (sum of bladder and rectum) for the nominal treatment plans 
created for specific aim 1 (uniformly weighted for proton arc therapy), and Figure 3.25 shows a 
histogram of this data for the medium patient. Additionally, the RRRs (ratios of ERRP Arc to 
ERRVMAT), are reported in Table 3.13 and plotted in Figure 3.26. For all risk models, the mean 
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ERR of all three patients following proton arc therapy was less than that following VMAT, 
yielding RRRs of less than one.  
Table 3.12 – Predicted excess relative risk of SMN incidence of the bladder and rectum for the 
nominal VMAT and proton arc therapy („P Arc‟) treatment plans for prostate cancer for the 
linear-no-threshold, linear-exponential, and the linear-plateau risk models for specific aim 1. 
The linear-exponential and linear-plateau models had inflection points at 10 Sv and 40 Sv. Risk 
was calculated for the small, medium, and large patients, as well as the mean of the three. This 
data is shown in histogram form in Figures 3.25 and 3.26. 
 
  
 
 
 
 
 
Figure 3.25 - The predicted excess relative risk of SMN incidence in the bladder and rectum 
for the medium patient following VMAT and uniformly weighted proton arc therapy for the 
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linear-no-threshold model, linear-exponential model with the inflection point at 10 Sv and 40 
Sv, respectively, and the linear-plateau model with the inflection point at 10 Sv and 40 Sv, 
respectively.   
 
 
Table 3.13 – The ratio of excess relative risk (RRR) following uniformly weighted proton arc 
therapy relative to the risk following VMAT for specific aim 1. An RRR (ERRP Arc/ERRVMAT) 
value less than one indicates a lower risk of SMN incidence following proton arc therapy.  
 
 
 
Figure 3.26 – The ratio of excess relative risk of SMN incidence (ERRP Arc/ERRVMAT) following 
uniformly weighted proton arc therapy relative to that following VMAT for the small, medium 
and large patient for the linear-no-threshold model, linear-exponential model with the inflection 
point at 10 Sv and 40 Sv, respectively, and the linear-plateau model with the inflection point at 
10 Sv and 40 Sv, respectively.  
 
 
 For specific aim 2, the risk following proton arc therapy with optimized non-uniform beam 
weighting was investigated. First, in order for the optimization algorithm to be able to minimize 
the risk, the risk contributed by each beam angle (or mirrored pair) had to be determined. Table 
3.14 and Figure 3.27 show the ERR calculated with the LNT model at each beam angle (or 
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mirrored pair) from therapeutic radiation assuming unit weighting for each. Then, the 
appropriate relative beam weighting to minimize the risk of SMN incidence of the bladder and 
rectum, bladder only, and rectum only (Table 3.15) was determined. Additionally, optimal 
weighting was found to minimize the risk of SMN incidence of the bladder and rectum for the 
scenario of a patient with a prosthetic hip (Table 3.16). The results of specific aim 2 are 
summarized and compared to specific aim 1 in Figure 3.28, below. 
Table 3.14 - The predicted LNT ERR of SMN incidence for the medium patient contributed by 
each proton beam or beam pair (therapeutic dose only). These reported risks are for each beam 
(or pair) as if it were 100% of the treatment. The beam angles listed are in degrees and refer to 
the left (L) and corresponding right (R) mirrored beams, respectively. 
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Figure 3.27 - The predicted LNT excess relative risk of SMN incidence for each proton beam 
or beam pair (therapeutic dose only). These reported risks are for each beam or beam pair 
normalized as if it were 100% of the treatment. It can be seen that there is a minimum in total 
risk for the 90 degree and 270 degree beam pair. 
 
Table 3.15 – The non-uniform relative proton beam weights found by the optimization 
algorithm and the resulting LNT excess relative risk (ERR) (risk from stray dose included) for 
plans optimized to minimize risk of SMN incidence in the bladder and rectum, bladder only, 
and rectum only for specific aim 2. The third to last row (Sum: ERRPArc) is the total ERR for the 
treatment. The second to last row is the ERR following the same (medium) patient‟s VMAT 
treatment plan from specific aim 1 (Table 3.12). The last row (RRR) is the ratio of ERRPArc to 
ERRVMAT. 
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Table 3.16 - The non-uniform beam weights found by the optimization algorithm and the 
resulting LNT risk (ERR) (risk from stray dose included) for the two prosthetic hip plans for 
specific aim 2. The third to last row (Sum: ERRPArc) is the total ERR for the treatment. The 
second to last row is the ERR following the same (medium) patient‟s VMAT treatment plan 
from specific aim 1 (Table 3.12). The last row (RRR) is the ratio of ERRPArc to ERRVMAT. 
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Figure 3.28 – The ratio of excess relative risk (RRR) of SMN incidence (ERRP Arc/ERRVMAT)  
following proton arc therapy relative to that following VMAT for the medium patient for the 
linear-no-threshold model. The RRRs from the proton arc therapy plans with non-uniform beam 
weighting optimized for objectives 1, 2, 3 and 4 (Table 2.5) are compared to the RRR from 
uniformly weighted proton arc therapy from specific aim 1   
 
 Specific aim 3 was designed to investigate the effect of margin size around the CTV to 
create the PTV on the predicted risk of SMN incidence following prostate radiotherapies. The 
predicted risk of SMN incidence in the bladder and rectum following VMAT and uniformly 
weighted proton arc therapy with varying margins for the medium patient is graphed below in 
Figures 3.29 through 3.31. First, Figure 3.29 shows the ERR of SMN incidence of the bladder, 
rectum, and the combination of the two organs calculated with the LNT model. It can be seen 
that the risk of SMN incidence in the bladder is higher than for the rectum and that risk 
increases as margin size increases for both. Then, the combined ERR of SMN incidence in the 
bladder and rectum for the LNT, linear-exponential, and linear-plateau models for VMAT and 
proton arc therapy is plotted in Figure 3.30. As expected, the linear-exponential and linear-
plateau prediction of ERR is less than for LNT. Finally, the RRR of SMN (ratio of ERRP Arc to 
ERRVMAT) is plotted in Figure 3.31. The LNT RRR is highest, around 1 (range: 1.00 – 1.08), 
showing little difference between the two modalities and a potential slight advantage for 
VMAT. The linear-exponential-10 RRR yielded the lowest RRR, 0.66, showing the largest 
advantage for proton arc therapy. As seen before in specific aim 1, all alternative risk models 
indicated an advantage for proton arc therapy with RRRs ranging from 0.66 to 0.93. While ERR 
generally increases with increasing margin size (within our bounds of 0 mm to 8 mm), a strong 
relationship between RRR and margin size was not observed.     
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Figure 3.29 – The predicted LNT excess relative risk of SMN incidence of the bladder and 
rectum and the combination of the two for the medium patient vs. the “else” margin around the 
CTV to create the PTV for VMAT and uniformly weighted proton arc therapy. The nominal 
expansion is 7 mm “else.” Posterior margins are 2 mm less than those graphed, except for 0 
mm “else” expansion, where the posterior margin is also 0 mm.  
 
Figure 3.30 – The predicted excess relative risk (RRR) of SMN incidence (combined bladder 
and rectum) for VMAT and uniformly weighted proton arc therapy for the medium patient for 
the linear-no-threshold model, linear-exponential model, and linear-plateau model vs. the “else” 
margin around the CTV to create the PTV. The nominal expansion is 7 mm “else.” Posterior 
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margins are 2 mm less than those graphed, except for 0 mm “else” expansion, where the 
posterior margin is also 0 mm. The linear-exponential and linear-plateau models have inflection 
points at 10 Sv and 40 Sv.  
 
 
Figure 3.31 – The predicted ratio of excess relative risk (RRR) of SMN incidence (combined 
bladder and rectum) for the medium patient for the linear-no-threshold model, linear-
exponential model, and linear-plateau model vs. the “else” margin around the CTV to create the 
PTV. The nominal expansion is 7 mm “else.” Posterior margins are 2 mm less than those 
graphed, except for 0 mm “else” expansion, where the posterior margin is also 0 mm. The 
linear-exponential and linear-plateau models have inflection points at 10 Sv and 40 Sv.  
 
 3.3.1 Statistical Analysis 
 The statistical analysis was performed to test the RRR values from specific aim 1 against 
the value of 1 (small sample size, n=3). When the sign test was conducted, the null hypothesis 
that P(+) ≥ P(–) (the probability of RRR > 1 being greater than or equal to the probability of 
RRR < 1) was rejected for all alternate risk models, but could not be rejected for the LNT 
model. Table 3.17 shows the p-values for the sign test for the different risk models, where red 
indicates a fail (p > 0.05; could not reject null hypothesis) and green indicates a pass (p < 0.05; 
rejected null hypothesis). 
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Table 3.17 - The results of the sign test which compared the RRR to 1. Red indicates a fail, 
where the null hypothesis that the P(+)≥P(–) cannot be rejected. Green indicates a pass, where 
the null hypothesis can be rejected, i.e. the RRR is significantly less than 1. 
 
 
 The t-test yielded similar results: the null hypothesis that the mean RRR  ≥ 1 was rejected 
for the alternate risk models, but could not be rejected for the LNT model. Table 3.18 shows 
the p-values for the t-test for all of the risk models, where red indicates a fail (p > 0.05; could 
not reject null hypothesis) and green indicates a pass (p < 0.05; rejected null hypothesis). 
Table 3.18 - The results of the t-test which compared the RRR to 1. Red indicates a fail, where 
the null hypothesis that the RRR ≥ 1 cannot be rejected. Green indicates a pass, where the null 
hypothesis can be rejected, i.e. the RRR is significantly less than 1. 
 
 
 3.3.2 Uncertainty Analysis 
 
 The uncertainty was estimated using propagation of the uncertainties of the components of 
the risk calculation (equations 2.16a and 2.16b). The uncertainty in the therapeutic absorbed 
dose from proton therapy was estimated to be 5% from the work of Giebeler et al. (2009). Two 
uncertainties contributed to the total uncertainty in the corrected VMAT dose: the uncertainty 
in the TPS VMAT dose (2% (Fontenot, 2008)) and the relative uncertainty in the correction 
method for VMAT (1.3% (section 3.2.1)). Therefore, the quadrature sum of 2% and 1.3% was 
used for the uncertainty in the corrected VMAT dose, 
V
D
D1
1 . The relative uncertainty in the 
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neutron dose from statistical fluctuations was found with a quadrature sum of the relative 
uncertainties of the neutron dose from each beam in the region of the bladder and rectum. The 
Rw
RRR
RRR
 and 
RM
RRR
RRR
 values were determined with sensitivity analysis, for which the 
results are listed in Tables 3.19 and 3.20, respectively.  Then, the covariance term was found to 
account for the effect of correlations in the data on the uncertainty. In this study, it was a 
negative term, which reduced the overall uncertainty. The absolute value of the covariance term 
was found to be 3.5% using equation 2.17 and the last term in equation 2.16. The final 
uncertainty in the mean RRR was asymmetric and calculated to be +1.2% and -22.7%. All 
uncertainty values are listed in Table 3.20 below. 
Table 3.19 – The mean LNT ERRs for uniformly weighted proton arc therapy and respective 
RRRs. As a sensitivity test, the mean radiation weighting factor for neutrons was varied by 
factors ranging from 0.5 to 5. The denominator for the mean RRR calculation (last row) is the 
LNT ERR for VMAT for each patient (Table 3.12).        
 
 
Table 3.20 – Assumed and calculated relative uncertainties for the error propagation and the 
resulting total uncertainty (equations 2.16a and b). The total uncertainties (positive and 
negative) are also reported in absolute terms of RRR (in parentheses). One σ corresponds to the 
68% confidence interval. 
Term Description Value [%] 
P
D
D1
1  
Uncertainty in therapeutic 
absorbed dose from proton 
arc therapy 
(TPS) 
5.0 
V
D
D1
1  
Uncertainty in dose from 
VMAT (corrected TPS: see 
section 3.2.1) 
2.4 
P
D
D2
2  
Statistical uncertainty in 
stray absorbed dose from 
proton arc therapy 
(Monte Carlo) 
< 1.0 
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Rw
RRR
RRR
 
Uncertainty contributed from 
Rw  
4.7 
RM
RRR
RRR
 
Uncertainty contributed from 
the risk model 
26.2 
PV
ERRERR
ERRERR
PV2  
Covariance term for VMAT 
and Proton Arc Therapy 
-3.5 
RRR
RRR  
Total positive uncertainty in 
mean RRR 
1.2 (0.01) 
RRR
RRR  
Total negative uncertainty in 
mean RRR 
22.7 (0.22) 
   
 In addition, the uncertainty was propagated for each patient individually, which can be seen 
as the error bars in Figure 3.32. 
 
Figure 3.32 – The predicted LNT RRRs for the small, medium and large patients (treatment 
plans from specific aim 1). The error bars correspond to the uncertainty propagated according 
to equations 2.18a and 2.18b. 
 
 Finally, uncertainty was also propagated for the mean RRR without the term that accounts 
for uncertainty in Rw . Then, the mean RRR was plotted vs. Rw  with error bars that correspond 
to the uncertainty in all factors except Rw  (Figure 3.33). 
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Figure 3.33 – Mean RRRs (Table 3.19; treatment plans from specific aim 1) vs. varying Rw  
with error bars that include all uncertainties considered, except those in Rw . 
 
 
Chapter 4 
Discussion and Conclusion 
 This chapter begins with a summary of the outcome of the specific aims (section 4.1) and a 
comparison with existing literature (section 4.2). Then, the implications and significance 
(section 4.3), strengths (section 4.4), and limitations (section 4.5) of this work are discussed. 
Finally, possible future work is mentioned (section 4.6) and the conclusions are stated (section 
4.7).  
4.1 Outcome of the Specific Aims 
 4.1.1 Outcome of Specific Aim 1 
 The goal of specific aim 1 was to predict the RRR of SMN incidence of the bladder and 
rectum following uniformly weighted proton arc therapy relative to that following VMAT 
using calculated dose distributions and risk models. Specifically, the LNT risk model was used 
to predict a baseline RRR, and the linear-exponential and the linear-plateau risk modes were 
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applied to estimate the impact on RRR from non-linearities in the risk model at high doses. The 
mean RRR for the LNT risk model was 0.99 (+ 0.01 or - 0.22; Table 3.20), which was shown to 
be not statistically different from 1. The reason for this similarity in LNT risk was that the 
mean doses to the bladder wall and rectal wall were comparable for both modalities. However, 
the distribution of the dose was more concentrated for proton arc therapy, which resulted in 
predicted RRRs that were statistically less than 1 for the other risk models. The mean RRRs 
were 0.74, 0.86, 0.84, and 0.91 for the linear-exponential-10 and -40, and linear-plateau-10 and 
-40 models, respectively. These results are 8% to 25% lower than the RRR obtained with the 
LNT model.   
 4.1.2 Outcome of Specific Aim 2  
 The goal of specific aim 2 was to investigate the effect on RRR of optimized proton beam 
weighting. Various host and treatment factors were considered, such as type of second cancer 
and avoidance of a hip prosthesis on the predicted risk following proton arc therapy. When the 
sum of LNT risk of SMN incidence in the bladder and rectum was minimized for proton arc 
therapy, the optimization yielded two lateral arc beams, resulting in an RRR of 0.87, compared 
to the RRR of 1.06 for uniformly weighted proton arc therapy. When the LNT risk of SMN 
incidence in the bladder or rectum alone was minimized, the predicted RRRs were 1.02 and 
1.07, respectively. Then, the constraint to avoid beams that passed through a prosthetic hip was 
applied while the risk of SMN incidence in the bladder and rectum combined was minimized, 
resulting in an RRR of 0.93.  
 The results of this specific aim show that optimized (non-uniform) beam weighting for 
proton arc therapy can significantly lower the predicted RRR of SMN incidence. As expected, 
the lowest RRR was achieved when the combined risk of SMN incidence in the bladder and 
rectum was minimized for the proton arc therapy plan. Another interesting result from this 
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specific aim is the optimal beam orientation to minimize risk of SMN incidence for a patient 
with a contralateral prosthetic hip while sparing the healthy femoral head.     
 4.1.3 Outcome of Specific Aim 3  
 The goal of specific aim 3 was to examine the sensitivity of the predicted risk of SMN 
incidence on the size of the expansion margin around the CTV following both proton arc 
therapy and VMAT. Using the LNT model, the ERR was found to vary between 6.83 and 10.07 
for proton arc therapy and 6.55 and 9.52 for VMAT, where risk increased with increasing 
margin size. The lowest ERR of SMN incidence was for the linear-exponential-10 model, 
which was found to vary between 0.88 and 0.90 for proton arc therapy and 1.28 and 1.32 for 
VMAT. In general, the ERR values calculated with the linear-exponential and linear-plateau 
risk models were less sensitive to margin size. Moreover, the RRR of SMN incidence was 
virtually independent of margin size for all risk models, with an average of 1.04, 0.69, 0.88, 
0.81 and 0.90 for the LNT, linear-exponential-10 and -40, and linear-plateau-10 and -40 
models, respectively.          
 4.2 Comparison with Existing Literature 
 The study most similar to this work is by Fontenot et al. (2009). In their study, the ERRs of 
SMN incidence in the bladder, rectum, and various out-of-field organs were calculated for the 
same three patients following parallel-opposed beam proton therapy and compared with 
corresponding ERRs following 6 MV IMRT. Additionally, they calculated the RRR for the 
medium patient with the same alternate risk models used in this work. They found the average 
RRR for all three patients to be 0.68 for the LNT model, and the RRR for the medium patient to 
be 0.66, 0.69, 0.69, 0.60, and 0.62 for the LNT, linear-exponential-10 and -40, and linear-
plateau-10 and -40 models, respectively. When only the colon and bladder are included in their 
calculation, the RRR for the medium patient becomes 0.65, 0.62, 0.64, 0.57, and 0.59 for the 
LNT, linear-exponential-10 and -40, and linear-plateau-10 and -40 models, respectively.  
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 The largest numerical difference between RRR predictions from the work of Fontenot et al. 
and this work was for the case of the LNT model: 0.66 vs. 1.06, respectively. An obvious 
source of this difference is that Fontenot et al. studied static-beam therapies, where we 
considered arc therapies. In our study, we found the ERR for equally-weighted 360 degree 
proton arc therapy to be considerably higher than for parallel-opposed beam proton therapy: 
11.51 vs. 7.97. This lower value for parallel-opposed beams compares fairly well to the ERR 
reported by Fontenot et al. for the bladder and colon of 6.24; however, there are other subtleties 
that account for the remaining discrepancy. First, Fontenot et al. used the whole organ volume 
(including contents), while we used the organ wall (excluding contents). We showed that this 
can have a significant impact on the mean organ dose, and therefore the LNT ERR. For 
example, in our study, the mean doses (therapeutic radiation only) to the bladder (and contents) 
and bladder wall from a parallel-opposed beam treatment were 9.34 Gy (RBE) and 13.40 Gy 
(RBE), respectively. Second, the mean dose to the target was slightly lower in the study by 
Fontenot et al. When their treatment plan was normalized to the same mean target dose as 
prescribed in our study, their mean doses to the bladder and bladder wall were 9.19 Gy (RBE) 
and 13.16 Gy (RBE), respectively, which agree very well with those from our study (listed 
above). To illustrate how this affects the risk, a table of the LNT ERR of SMN incidence in the 
bladder (and contents), bladder wall, rectum (and contents), and rectal wall from therapeutic 
dose is shown below (Table 4.1) for the two studies (normalized to the same target dose).  
Table 4.1 - The therapeutic dose component of ERR for the treatment plans in this study (LR) 
and the study by Fontenot et al. (2009) (JF) calculated with the LNT model for the bladder (and 
contents), bladder wall, rectum (and contents), and rectal wall. Note the increase in risk when 
the organ walls were used instead of the whole organ. For the proton plans (last three columns) 
„2 beam‟ refers to a parallel-opposed proton beam treatment for prostate (accomplished with 
weighting for the proton arc plan), where „Uniform‟ refers to the 360 degree, uniformly 
weighted proton arc treatment plan. While the „2 beam‟ proton plans have comparable risk, the 
„Uniform‟ proton arc treatment plan has higher risk.  
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Therefore, when differences in planning technique (arc plans vs. static beam plans, prescription 
dose) and volume contouring (wall volumes vs. whole organ volumes including contents) are 
considered, our results agree well with those from Fontenot et al.  
  Schneider et al. (2007) also published a study that is relevant to this work. In their study, 
the whole-body secondary cancer risk of spot-scanned proton radiotherapy relative to 6 MV 
IMRT was found to be 0.49, 0.50, and 0.51 for the LNT, linear-exponential, and linear-plateau 
models, respectively. Because of the spot-scanning delivery, dose from external neutrons was 
minor, in contrast to our work, where it comprises approximately one third of the neutron dose. 
However, the contribution of external neutron dose to the total risk was minimal: 
approximately 2%. Another difference in their study is that they did not do tissue-specific risk 
calculations; they estimated risk to a “whole-body” contour. Despite the differences in the 
methods, our results are remarkably consistent with the results from Schneider et al.   
 This study is not consistent with the work of Dasu et al. (2011). They predicted the risk of 
second cancers in the bladder and rectum following 3DCRT of the prostate for “narrow” 
margins (4 mm in the posterior direction, 6 mm in other directions) and “wide” margins (10 
mm in the posterior direction, 15 mm in other directions) around the CTV. They predicted risk 
using a model based on the single-dose competition model proposed by UNSCEAR (1993), 
which is similar to the linear-exponential model in our work. They found that the risk decreased 
with larger margins, whereas we found that risk either remained approximately constant 
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(linear-exponential-10) or increased slightly (linear-exponential-40) with margin size (Figure 
3.30). However, there are a few major differences in our studies. First, the risk model used by 
Dasu et al. peaks at about 4 Gy, where ours peaked at either 10 or 40 Gy (Gy is equivalent to 
Sv for photons). Second, the distribution of dose for 3DCRT treatment plans could be 
significantly different from the distribution of dose for our VMAT and proton arc therapy 
treatment plans. Finally, the “wide” margins used in their work were considerably larger than 
the largest margins investigated in our work (10 mm vs. 6 mm in the posterior direction, and 15 
mm vs. 8 mm in other directions, respectively). It is possible that these differences account for 
the discrepancy in the results between the two studies.                             
4.3 Implications and Significance of this Study 
 Due to the large population of patients who receive prostate radiotherapy, even a small 
increase or decrease in risk of cancer due to radiation exposure could have a significant impact 
on public health. Therefore, risk of SMN incidence following treatment should be considered, 
along with many factors, in the clinical and policy decision making. The significance of this 
work is that it characterizes the risk of SMN incidence following two types of radiotherapy for 
prostate cancer: VMAT and proton arc therapy.  
 Previous to this work, the risks of SMNs following radiation arc therapies using VMAT and 
proton arc therapy were unknown. In this work, the ERR and RRR for the two modalities were 
characterized for the two modalities for a variety of host and treatment factors: patient size, 
proton arc therapy beam weighting, mean neutron radiation weighting factor, risk model, and 
margin size.  
 Another finding of this work was the ideal proton beam arrangement to minimize the risk of 
SMN in the bladder and rectum for a patient with a prosthetic hip. It is possible that this finding 
could be one factor in the choice of beam angles for such patients.  
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 In addition, this study found that two lateral-opposed proton beams is the ideal arrangement 
to minimize the risk of second cancers of the bladder and rectum following prostate 
radiotherapy. This result is encouraging in regard to statically delivered proton therapy, because 
it strengthens the rationale for the beam arrangement in the current standard-of-care used for 
treating for prostate cancer. However, it is something that should be taken into consideration in 
the development of proton arc therapy. Therefore, an implication of this finding is that it would 
be advantageous for a proton arc therapy machine, which has been proposed but not yet built, 
to have the capability to deliver this type of lateral-opposed treatment, e.g. static or near-static 
beam delivery capacity. 
4.4 Strengths of this Study 
 This study has several noteworthy strengths. First, to our knowledge, this was the first study 
to explicitly and algorithmically minimize the risk of second cancer by varying proton beam 
weights. Others have investigated minimizing risk through choice of treatment modality 
(Miralbell et al., 2002; Mu et al., 2005; Schneider et al., 2006; Fontenot et al., 2009; 
Newhauser et al., 2009a; Bednarz et al., 2010) or optimizing treatment plans for uncertainties 
(Pflugfelder et al., 2008; Unkelbach et al., 2009) or RBE (Wilkens and Oelfke, 2005), but this 
was the first study to specifically optimize treatment plans to minimize the risk of second 
cancers. This method could be expanded upon and applied to other treatment sites. In the 
future, minimizing a patient‟s risk for developing a second cancer could be one of the many 
factors in personalized cancer radiotherapy.  
 Additionally, our study was the first to estimate the risk of SMN incidence following 
VMAT for prostate cancer. Surprisingly, we found the risk of SMN in the bladder and rectum 
following VMAT to be lower than following IMRT. This result is of particular interest due to 
the recent expansion of VMAT and because of the ubiquity of photon-based external beam 
radiotherapy for prostate cancer.  
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 Another strength of this study was the level of detail of the dose determination and risk 
estimation. Differential DVHs were exported from the TPS for the bladder and rectum, 
excluding the contents, and stray dose was estimated or calculated where possible. Then, age-, 
sex-, and organ-specific parameters were obtained from BEIR VII, used to estimate the LNT 
risk, and modulated to model cell sterilization with the linear-exponential and linear-plateau 
risk models. 
 Finally, the uncertainty analysis was a strength of this work. Other similar works mention 
the uncertainties associated with risk predictions (Kry et al., 2005a; Schneider et al., 2007; 
Bednarz et al., 2010) but did not report a full uncertainty propagation. In this work, we 
extended and adapted the uncertainty analysis of Fontenot et al. (2008; 2010) and included 
uncertainties in the dose (both therapeutic and stray), the neutron radiation weighting factor, 
and the risk model.      
4.5 Limitations of this Study 
 There are several limitations of this study. First, only the risk of SMNs of the bladder and 
rectum were considered. This is not a serious limitation, however, because doses to the bladder 
and rectum account for the vast majority of the risk (Fontenot et al., 2009); the risks of SMN 
incidence in the bone marrow, skin, and out-of-field organs, which were not included in this 
study, are of lesser importance.   
 Moreover, the metric used in this work to express risk of SMN, ERR, has limitations of its 
own. ERR is an instantaneous quantity, describing the excess relative risk at a given point in 
time. In this work, the ERR at 10 years post-treatment was chosen as a meaningful surrogate for 
the lifetime ERR for the purposes of estimating RRR, giving the typical age of prostate cancer 
patients. Therefore, this is not a major limitation of this work. 
 Additionally, only three patients were studied in this work. While a strong dependence on 
patient-specific differences (patient size, internal anatomy) was not observed in this work, the 
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sample size was small. Studying a larger patient population would elucidate the dosimetric 
impact of inter-patient anatomical differences, and might make it possible to see a larger, 
statistically significant difference in the predicted mean RRR value.    
 Another limitation of this study was that risk-optimized treatment planning was not 
explicitly available for VMAT. However, the inverse planning method used for all of the 
VMAT treatment plans was conceptually and functionally similar to the risk-optimized 
planning method utilized for the proton arc therapy treatment plans for specific aim 2. Both 
optimization methods minimized the dose to organs of interest: e.g. the bladder and/or rectum. 
The VMAT inverse planning system accomplished this with a cost function that was based on 
DVH objectives and constraints for the organs of interest. The risk-minimized proton arc 
therapy treatment planning method also minimized dose to the bladder and rectum with a cost 
function, which was based on mean organ dose. Because of these similarities, we believe that 
the comparison between the modalities was reasonable. For future work, it would be interesting 
to investigate risk-optimized planning for VMAT.  
 Furthermore, range compensators were used to create distal conformity for the proton arc 
treatment plans in this study. If this technique was implemented using passive scattering, 
different range compensators could not be used for each beam. Either one generic range 
compensator could be used, or none at all. However, the goal of this study was to investigate 
the risk of SMN incidence following proton arc therapy in general, not to address all of the 
design challenges of implementing proton arc therapy on a passively scattered system. 
Additionally, if scanned beam delivery was used for proton arc therapy, which has its own 
engineering challenges, range compensators would not be necessary for distal conformity.    
 The final noteworthy limitation is that variations in the dose distribution (beyond those 
observed in our sample) were not considered in the uncertainty analysis of RRR. The dose 
distribution for both modalities could be affected by uncertainty in the beam calibration, setup 
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errors, varying field size, and differences in anatomy. In particular, the dose distribution for 
proton arc therapy could also be affected by the beam range, SOBP width, and the air gap.  
4.6 Future Work 
  Treatment-specific measurements to validate the stray dose that was estimated and 
simulated for this work would lend additional confidence to their accuracy. Due to the 
difficulty of detecting high-energy neutrons, the stray dose from proton arc therapy would have 
to be measured with a special detector like an extended Bonner Sphere system (Howell, 2009) 
or a WENDI-II (Olsher and McLean, 2008). Additionally, stray dose from VMAT has not been 
explicitly characterized. Even though extensive stray dose measurements have been made for 
IMRT (Kry et al., 2005b; Howell et al., 2006), verifying that the stray doses between the two 
modalities are equivalent would be valuable.        
 This work focused on SMNs of the bladder and rectum. For a more complete representation 
of the risk of SMN incidence following radiotherapy, the risk calculations could be expanded to 
include bone marrow, skin, and other out-of-field organs. However, the BEIR VII report does 
not include specific risk prediction information for skin, and excludes non-melanoma skin 
cancers. Therefore, another reference would be required for the inclusion of skin, for example, 
Publication 60 of the ICRP (1991). Also, our patient CT datasets did not span the entire body, 
so additional whole-body phantoms would be necessary for the Monte Carlo simulations. 
 Finally, this work could be expanded to other treatment sites and patient populations. A 
different treatment location yields different doses to organs, thus producing a different risk 
profile. A different patient population would have a different risk of second cancer based on 
age at exposure and life expectancy. For example, children treated with radiation have an 
increased risk of cancer due to increased radiosensitivity (ICRP, 1991) and the potential for a 
longer life expectancy post treatment. Because of these factors, it would be particularly 
   
 96 
meaningful to study and minimize the predicted risk of second cancers following radiotherapy 
for pediatric patients. 
4.7 Conclusions 
 Proton arc therapy significantly reduces the predicted risk of incidence of radiogenic second 
malignant neoplasms (SMNs) in the bladder and rectum following prostate radiotherapy 
compared to VMAT when predicted with the linear-exponential and linear-plateau risk models. 
On the other hand, no significant difference was seen between the modalities when the risk was 
predicted with the linear-no-threshold (LNT) model. When the beam weighting for proton arc 
therapy was optimized to minimize the LNT risk of SMN incidence, a reduction of risk was 
observed compared to VMAT: RRR was reduced from 1.06 to 0.87. Additionally, it was found 
that while excess relative risk (ERR) of SMN incidence increased with PTV margin size for 
both modalities, the ratio of excess relative risk (RRR) between the two modalities was virtually 
independent of margin size.  
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